THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference and Administrative Details of the Company, its Trustees and Advisers</td>
<td>1</td>
</tr>
<tr>
<td>Trustees' Report</td>
<td>2 - 16</td>
</tr>
<tr>
<td>Trustees' Responsibilities Statement</td>
<td>17</td>
</tr>
<tr>
<td>Independent Auditors' Report on the Financial Statements</td>
<td>18 - 21</td>
</tr>
<tr>
<td>Statement of Financial Activities</td>
<td>22</td>
</tr>
<tr>
<td>Balance Sheet</td>
<td>23</td>
</tr>
<tr>
<td>Statement of Cash Flows</td>
<td>24</td>
</tr>
<tr>
<td>Notes to the Financial Statements</td>
<td>25 - 44</td>
</tr>
</tbody>
</table>
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2022

Trustees
V Paçes, Secretary General (appointed 1 January 2017, term ended 31 December 2022)
P Laidler, Chair Executive Committee (appointed 1 January 2020)
F Michelangeli, Treasurer (appointed 1 January 2017)
F G Sağın, Chair, Education Committee (appointed 1 January 2019)
I Diaz Moreno, Chair, Working Group on the Careers of Young Scientists
(appointed 1 January 2018)
C Arraiano, Chair, Working Group on Women in Science (appointed 1 January 2014, term ended 31 December 2022)
B Vértessy, Chair, Advanced Courses Committee (appointed 1 January 2015)
M De La Rosa, Congress Counsellor (appointed 1 January 2013)
J Dumić, Chair, Working Group on Integration (appointed 1 January 2017)
E Fragkoulis, Chair, Science and Society Committee (appointed 1 January 2017)
A Krol, Chair, Fellowships Committee (appointed 1 January 2017)
J Kos, Vice Chair Executive Committee (appointed 1 January 2021)
J Buchner, Chair, Publications Committee (appointed 1 January 2021)
X D C Coumoul, Chair, Network Working Group (appointed 1 January 2022)
C Dean, Chair, Working Group on Women in Science (appointed 1 January 2023)
G Severa, Vice Chair Executive Committee (appointed 1 January 2023)

Company registered number
08239097

Charity registered number
1149638

Registered office
St Andrew's House Suite B1 Third Floor, 59 St Andrew's Street, Cambridge, CB2 3BZ

Company secretary
Professor M De La Rosa

Independent auditors
Hill Wooldridge & Co. Limited, 107 Hindes Road, Harrow, Middlesex, HA1 1RU

Bankers
HSBC UK Bank PLC, 1st Floor, Sunningdale, The Belfry Business Park, Colonial Way, Watford, WD24 4WH

Investment managers
J.P. Morgan Private Bank, 60 Victoria Embankment, London, EC4Y 0JP
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES’ REPORT
FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees present their annual report together with the audited financial statements of the Company for the year 1 January 2022 to 31 December 2022. The Annual Report serves the purposes of both a Trustees’ report and a directors’ report under company law. The Trustees confirm that the Annual Report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company’s governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors’ Report) Regulations 2013 has been omitted.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Constitution
FEBS is registered as a charity (registered charity number 1149638), and is a company limited by guarantee (registered company number 08239097). The Memorandum and Articles of Association by which FEBS was governed in 2022 can be found here: https://www.febs.org/wp-content/uploads/2022/08/FEBS_Memorandum_and_Articles_of_Association.pdf.

Organisation and membership
FEBS was founded on 1st January 1964 and is a Federation of biochemistry and molecular biology societies. In 2022, its Constituent Societies spanned 39 countries in Europe and neighbouring regions and included 35 Member Societies and 4 Associate Member Societies. The Constituent Societies of the Federation in 2022 are given in Appendix 1, and their membership numbers in Appendix 2 (totaling 25,636 individual members in 2022). (2 societies – Russia and Belarus – had their membership of FEBS suspended following a Council vote in 2022 and they currently remain suspended.)

FEBS is governed by a Council composed of one delegate from each of the Constituent Societies as well as the members of the Executive Committee. FEBS Council meets once a year at the annual FEBS Congress. The Council elects members of the FEBS Executive Committee for three-year terms (except the Chair and Vice-Chair positions), as well as ordinary members of the FEBS Committees and Working Groups (delegated specific areas of FEBS work) for four-year terms, in a secret ballot. The Vice-Chair of the Executive Committee, who after one year becomes Chair, is appointed by the Society hosting the annual Congress and Council Meeting in the previous year.

Subject to the Council, the administration of the Federation is vested in the FEBS Executive Committee (the ‘FEBS Officers’). The Executive Committee consists of the Chairperson, the Vice-Chairperson, the FEBS Secretary General, the FEBS Treasurer, the FEBS Congress Counsellor, and the FEBS Committee and Working Group Chairpersons. With the exception of co-opted Acting Chairpersons (e.g. following resignations prior to Council elections), FEBS Officers are the FEBS charity Trustees and company Directors responsible for the actions of FEBS. The names of the members of the Executive Committee and the names of members of other Committees and Working Groups in 2022, together with dates of appointments and geographical distribution, are set out in Appendix 3.

The FEBS Trustees/Directors are distinguished scientists and (with the exception of the Executive Committee Vice Chair and Chair, as explained above) elected by FEBS Council from nominations put forward by FEBS Constituent Societies. Before formal appointment, newly elected Trustees/Directors sign the Charity Commission’s ‘Declaration of eligibility for newly appointed Trustees’ and are referred to the Charity Commission’s guidance on the role of Trustees as well as Companies House information on Director/Secretary roles.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES’ REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

OBJECTIVES AND ACTIVITIES

Objectives
The objectives of FEBS are to contribute to and promote the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines (but only in so far as such related disciplines are ancillary to the main object), by all suitable means and in particular by:

- holding and arranging congresses, training and educational courses on matters connected with biochemistry and molecular biology and related disciplines.
- facilitating and supporting the exchange of scientific information between biochemists, molecular biologists and scientists working in related disciplines generally and especially in Europe and other countries of Constituent Societies.
- facilitating and supporting the training of young scientists in research, in the form of fellowships; and
- organising the editing and publication of scientific research and educational material in biochemistry and molecular biology and related disciplines.

Activities
The following paragraphs and their associated appendices outline activities in 2022 from the different Committees and Working Groups of FEBS. Extensive information on FEBS work is also available on the FEBS website at www.febs.org, and highlights appeared in the issue of FEBS News (pdf magazine) in 2022: www.febs.org/news/febs-news-magazine/.

Scientific publications
FEBS owns four journals for the publication of research papers, reviews and discussion in the molecular life sciences: The FEBS Journal, FEBS Letters, Molecular Oncology and FEBS Open Bio. They are published on behalf of FEBS by Wiley and aim to provide high-quality peer review, fast publication, and a variety of enhanced features for both authors and readers. The journals provide most of the income to fund FEBS’ other activities.

The Publications Committee oversees the operation and development of FEBS’ journals and in 2022 was under the chairmanship of Johannes Buchner. All four journals are internationally recognised to be of high quality as detailed below. The four journals are fully digital and can be reached through the FEBS Press platform (www.febsspress.com).

The FEBS Press journals have embraced changing publishing practices and offer simple submission in any format and a smooth publication process, with peer review managed by editorial board members who are experts in the field. Thorough ethics and research integrity checks are run by our experienced editorial staff prior to article publication. All journals now publish peer review reports alongside research articles. Authors of articles rejected by one FEBS Press journal can choose to have their manuscript automatically transferred to another. All journals offer open access options; over 60% of total articles published in 2022 were open access (vs 59% in 2021).

- The FEBS Journal (www.febssjournal.org) publishes high-quality full-length research papers relevant to the molecular, cellular and biochemical life sciences. The journal also publishes a diverse portfolio of commissioned front-half content review and editorial content, including State-of-the-Art Reviews, Commentaries, Discovery-in-Context Reviews, Structural Snapshots, Viewpoints, Words-of-Advice guides and interviews with eminent scientists (In Conversation With ...). Key metrics for 2022: Impact Factor 5.4, CiteScore 10.1, Cited Half-life 8.7 years, Median time from submission to first decision after peer review 38 days. In 2022, the journal published 470 articles in 24 issues. Authors have the option of publishing their article open access.

- FEBS Letters (www.febsletters.org), publishes research reports (both short Letters and full-length articles) that significantly impact and advance knowledge in the molecular biosciences; editorial speed is a key feature of the journal. The journal also publishes a diverse range of Reviews (including in a Nutshell and Perspectives) and other front-half content (Commentaries, Scientists’ Forum). Key metrics for 2022: Impact Factor 3.5, CiteScore 7.0, Cited Half-Life 16.8 years, Median time for submissions to first decision after peer review 22 days.
In 2022, the journal published 269 articles in 24 issues. Authors have the option of publishing their article open access.

- Molecular Oncology (www.moloncol.org) publishes high-impact research articles in basic, translational and clinical cancer research. The journal also publishes commissioned reviews and policy papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Key metrics for 2022: Impact factor 6.6, CiteScore 11.8, Cited Half-life 4.5 years, Median time from submission to first decision after peer review 41 days. In 2022, 230 articles were published in 22 issues. The journal is full open access.

- FEBS Open Bio (www.febsoopenbio.org), publishes research articles across the molecular and cellular life sciences, with the emphasis on technical and ethical quality rather than subjective judgements of significance. Research articles on Education in the molecular life sciences are published free of charge. Key metrics for 2022: Impact factor 2.6, CiteScore 4.7, Cited Half-life 3.7 years, Median time from submission to first decision after peer review 33 days. In 2022, 171 articles were published in 12 issues. The journal is full Open Access.

The FEBS Network
The ‘FEBS Network’ platform, (1) hosts blog-type posts offering insight, advice, news and commentaries for molecular life scientists (under the themes Early-Career Scientist, Educator, Viewpoints and Research), and (2) supports the development of an online community of scientists through presentation of profiles, and functionalities such as following, commenting and open or private rooms. It also offers a channel for posts and a private room for FEBS Constituent Societies, and hosts videos such as interviews and recorded talks. The FEBS Network in 2022 was overseen by the FEBS Network Working Group, comprising scientists delegated from other FEBS Committees or elected and chaired by Prof. Xavier Coumoul. Wiley had offered collaboration to develop a FEBS Network in the journal Publishing Agreement 2016–2023 and bears the cost of the software provision from the platform provider, Zapnito. The current aims of the FEBS Network include (1) supporting and enhancing the key FEBS activities of journals and events, as well as other FEBS work such as education, science & society and fellowships; (2) providing an innovative offering from FEBS as a new way to support the molecular life sciences community; and (3) building more access to scientists interested in FEBS activities.

FEBS Fellowships
The report from the 2022 Chairman of the Fellowships Committee, Prof. Alain Krol, provides information on the range of applications received for the various categories of Fellowships. Following the final call for Long-Term Fellowships (LTF) in 2020 (when 77 applications were received), 6 new Fellowships were awarded and were taken up from January 2021, the total in post during 2022 was 5 (Appendix 4) and the LTF’s final year in post is 2024.

39 eligible Short-term Fellowships (STFs) applications were received in 2022 and 22 were awarded. These funds enable active young scientists to work for up to two or three months in laboratories in another FEBS country. In 2022, 31 eligible Summer Fellowship applications were received and 10 were awarded to promising Masters/PhD students to provide a laboratory experience. 5 Collaborative Experimental Scholarship (CDS) applications were received in 2022, of which 4 were awarded; the aim of the CDS is to provide PhD students and young scientists from HINARI (Research4Life) countries with travel and daily allowance so that they can carry out experiments which would be impossible in their home countries.

FEBS Excellence Award
The first call for this new program was made in June 2021. This award is intended for early-career scientists who have been established in a salaried capacity in a host institution of a FEBS Constituent Society as a Principal Investigator (PI) for at least one year. The Award is endowed with a €100,000 grant for 3 years to be used exclusively for purchasing consumable/equipment. In 2022, 16 eligible applications were received and 10 were awarded.

Ukrainian Short-Term Fellowships (USTs): these were introduced in spring 2022 to help scientists in or displaced from Ukraine. They support visits to a host laboratory for up to 4 months. The decision for acceptance is given rapidly - usually within 3 weeks of applying. 10 USTs were awarded in 2022, the majority of them for a 4 month period, and occasionally for 3 months.
Advanced Courses
Following the COVID-19 pandemic, 25 personal events took place in 2022 (8 Advanced Lecture Courses, 7 joint FEBS-EMBO Lecture Courses, 3 Practical Courses, 2 Practical and Lecture Courses and 5 Workshops) with continued EMBO and IUBMB support. FEBS Advanced Courses provide research updates and teaching from scientific leaders in a particular field and are particularly valuable for early-career researchers. Interaction of participants with experts and peers is facilitated through a variety of session formats.

In 2022, grants to course organisers totalled approximately €416,000. Furthermore, Youth Travel Fund (YTF) grants, which in 2022 totalled €90,000, were given to support participation in Advanced Courses to 81 young members of FEBS Constituent Societies from outside the host country (19 YTFs were given in 2021). In addition, 8 IUBMB-transcontinental YTFs supported the participation of students outside FEBS area.

A collaboration continued between FEBS Advanced Courses Committee and FEBS Letters, which was initiated in 2019. Organisers are encouraged to participate in providing high-quality material in a form of a Special Issue or a Virtual Issue in order to provide the course organisers with the opportunity to gain broad visibility of their work in a well-reputed journal.

The 46th FEBS Congress
The annual FEBS Congress is overseen by the FEBS Congress Counsellor (who, in 2022, was Prof. Miguel A. De la Rosa), jointly with the Secretary General (who, in 2022, was Prof. Václav Paříček). The 46th FEBS Congress was held jointly with IUBMB and PABMB, as one single global event named The Biochemistry Global Summit, which took place from 9th to 14th July 2022 in Lisbon, Portugal and was hosted by the Portuguese Biochemical Society (SPB). The Congress bid was accepted in a vote by the FEBS Council at their meeting in 2018 and was due to be held in 2021, but, due to the ongoing COVID-19 pandemic, the Congress was postponed to 2022.

Despite the impact of the pandemic, war and rising inflation, the Congress attracted 1,350 participants from 62 countries and the event featured an attractive scientific program comprising 12 plenary lectures, 36 symposia topics arranged under 7 broad themes, 49 invited symposia speakers, 6 special sessions including Research and Career Skills, Science and Society, Education and Gender Issues and 109 short talk speakers. The program also featured 902 posters from the submitted abstracts.

Following the decision taken by FEBS Council (elaborated below), FEBS provided specific additional funding support for Ukrainian scientists or displaced from Ukraine who are submitting abstracts to the IUBMB–FEBS–PABMB Congress.

In addition to providing a grant for the organisation of the Congress, FEBS continues to support the participation of young scientists at the event through Congress bursaries and through its Young Scientists' Forum awards (usually 100 participants, including the organising committee). FEBS provides support with reduced registration fees for FEBS members of Hinari B countries in the FEBS area called the Sprinzl Scheme.

Congress Management and Development and future Congresses
With the postponed 45th Congress held in 2021 and 46th Congress held in 2022, the subsequent FEBS Congresses and Young Scientist Forums (YSF) were also postponed by one year as follows:

- the 47th FEBS Congress and preceding 22nd FEBS YSF will now be taking place in July 2023 in Tours, France following a decision taken in March 2022, by the FEBS Executive Committee and endorsed by FEBS Council, regarding to cancel the 2023 Congress host location of Moscow, Russia in light of the Russian attacks on Ukraine (and suspension of the Russian and Belarusian societies from FEBS activities).
- the 48th FEBS Congress bid from the Italian Society of Biochemistry and Molecular Biology (SiB) was approved and will take place in Milan, Italy in 2024, preceded by the 23rd FEBS YSF.

FEBS continues to take out a cancellation insurance policy for each Congress and, although event insurance cover has changed because of the COVID-19 pandemic, FEBS continues to take out this insurance policy, as an example of FEBS' responsibilities as a charity to manage risk and effectively deliver its aims, along with the
contracts in place with the Professional Congress organiser (PCO) and Host Society.

Young Scientists' Forum (YSF)
The Chairperson of the Working Group on the Careers of Young Scientists, Prof. Irene Diaz-Moreno, and an organising committee of young scientists organise the YSF. The 21st YSF took place in conjunction with IUBMB and PABMB and was held in Vimeiro, Portugal 6th – 9th July 2022. 209 applications were received from 27 countries and 110 pre-and post-doctoral young scientists, including 100 from FEBS member societies, representing 33 countries from all over the world including 26 FEBS member society countries, attended the event, supported by grants from FEBS, IUBMB and PABMB. The program consisted of 4 Keynote Lectures, 9 'YSF Career Speakers' across 3 sessions on 'Career Skills', 'Science from another point of view' and 'Fellowships Insights', 3 Selected Oral Communication sessions, Poster Presentation sessions, as well as social activities. YSF participants also attend the Congress, during which the YSF Bridge event was held.

In conjunction with the decision to hold the 47th FEBS Congress in Tours, France, it was also decided to hold the 22nd YSF in the same location on 6th to 8th July, to be followed by the Congress. This event was organised by the Chairperson and an international organising committee of young scientists.

ENABLE
During the period 2017 to 2021, FEBS and IUBMB were the main sponsors of the ENABLE events. As agreed in 2021, for the event organisation, FEBS and IUBMB will work with the ENABLE core partner European institute, who will be appointed following an open call for bids and who will act as the host and take responsibility for the Symposium each year. There will also be a Scientific Organising Committee and Local Organising Committee. The agreement runs from 2022 to 2025. The FEBS-IUBMB-ENABLE Symposium is held in Europe in 2022 and 2023, outside Europe in 2024 and in Europe again in 2025. Travel grant support will be provided to young scientists.

The FEBS-IUBMB-ENABLE 2022 conference, with the title "The perfect tandem: How technology expands the frontiers of biomedicine", was hosted by the Institute of Biomedicine of Seville (IBIS), in Spain, on 16–18 November 2022. 300 young researchers participated from 31 countries within and outside of the EU. The conference included a scientific symposium but also outreach activities for the general public and a dedicated career day. 10 sponsors supported this initiative and their contribution allowed support to be given for a total of 74 travel grants.

FEBS 3+ Meetings and FEBS National Lectures
FEBS supports scientific events of its Constituent Societies through the FEBS3+ meetings program and the FEBS National Lecture scheme, overseen by the FEBS Congress Counsellor (Prof. Miguel A. De la Rosa in 2022). The FEBS3+ meetings program provides funding for meetings organised through collaborations of at least three FEBS Constituent Societies. FEBS approved applications for two FEBS3+ meetings which took place in 2022. The Machines on Genes meeting hosted by the Biochemical Society (UK) and held in Alicante, Spain in conjunction with NVBMB (The Netherlands) and SEBBM (Spain) took place in May 2022, having been postponed from 2021 due to the COVID-19 pandemic. This meeting featured 3 plenary speakers, 7 symposia sessions, poster abstracts and oral talks with 47 poster presenters. The Baltic Meeting, hosted by the Estonian Biochemical Society in conjunction with LaBS (Latvia society) and LBD (Lithuania society), took place in Tallinn, Estonia in June 2022. The meeting in Estonia included 210 participants (90 from Estonia, 58 from Lithuania and 38 from Latvia), 4 plenary talks amongst 30 scientific talks including from graduates and PhD-level scientists across six single and two parallel sessions, as well as 77 posters and industry support. FEBS support consists of €10,000 to the host society for general meeting organisation and €10,000 to support the attendance of young scientists from the other participating societies.

In 2022, FEBS supported 10 FEBS National Lectures, by funding the attendance of key speakers from a different FEBS country invited by a FEBS Constituent Society to their national meeting through FEBS National Lecture Awards. The ten FEBS National Lectures were awarded to national society meetings of the member societies of Croatia, Cyprus, Finland, France, Italy, Latvia, Spain, Sweden, Tunisia and Turkey (following the postponement of many national society meetings during the pandemic).
Other events
In the framework of promoting FEBS' journals and FEBS' collaborations with related international organisations of molecular life sciences, FEBS continues to support, through sponsorship of events and travel costs for distinguished speakers to deliver lectures at annual meetings of learned societies of biochemistry/molecular biology/cell biology in parts of the world with rapidly developing contributions to molecular life sciences research.

Science & Society (S&S)
The Science and Society Committee activities in the year 2022 included:
1. the Science and Society Special Session at the IUBMB-FEBS-PABMB Congress in Lisbon, July 2022 on "RNA Solutions to genetic and infectious diseases" featuring invited speakers from the Netherlands, Spain and the USA;
2. expanding on the topic of 'Plastics: revolution, pollution and substitution' from the 2021 FEBS Congress by providing support to constituent society events and activities on this theme being held in 2022. Following a call for proposals, the Science and Society Committee provided grants of €1,500 to the Italian Society of Biochemistry and Molecular Biology (SIB) for their public engagement event 'I'm in plastic: it's not fantastic' in November 2022 and to the Spanish Society for Biochemistry and Molecular Biology (SEBBM) for a video project entitled "How can bioplastics contribute to diminish plastic pollution?"
3. Participation in Biomedical Alliance activities. Through active participation in activities of Biomedical Alliance (General Assemblies, Policy officers' meetings and task forces) the S&S Committee contributed in several suggested documents for the shaping of European policy, including participating with other organisations to obtain from the EU the best research budget for the Framework Program FP9.
4. Participation in the FEBS Network.

Education
The Education Committee has the mission of promoting education and training of the highest quality in molecular life sciences in Europe at both undergraduate and postgraduate levels. The committee's activities include: organising and funding education events, running the Education Ambassadors initiative, supporting the open access journal FEBS Open Bio's section devoted to education and overseeing and contributing to the Educator Channel on the FEBS Network. FEBS Education Committee also works collaboratively with FEBS AdvancedCourses Committee and FEBS Working Group on the Careers of Young Scientists. This is the report from the Chairperson, Prof. Ferhan Sağın on Education Committee activities planned for 2022.

Education Committee Meetings: the committee met in-person in May 2022 in Izmir, Türkiye (for the first time since the pandemic) prior to the Ambassadors Meeting; a second committee meeting was held in October 2022 in Split, Croatia, prior to the Education Workshop event. Four online meetings were also held.

6th FEBS Education Ambassadors' Meeting
The 6th FEBS Education Ambassadors Meeting took place in Izmir, Türkiye on 19 – 20 May 2022, with 28 ambassadors in attendance. The meeting program included on day one: 5 short presentations from ambassadors sharing their education activities in the past year, a panel discussion with three talks focused on the history and aims of the Ambassadors initiative, the importance of education in the mission and vision of FEBS and the roles and functions of the Ambassadors based on the 2021 SWOT analysis undertaken, followed by group activities on specific themes; and on day two: a talk on 'Education research and challenges achieving publication' followed by group activities on specific themes and a final talk on 'accreditation of molecular bioscience degrees in Europe'.

Education Committee Seasonal Webinars
The seasonal webinar series which started in 2021 continued in 2022, with:
Spring webinar entitled 'Visualization in science education: emerging opportunities for making the invisible visible';
Summer webinar entitled 'How to support sustainable supervision of doctoral researchers';
Autumn webinar entitled 'Development of a teaching module for PhD candidates'; and
Winter webinar entitled 'Assessment 101 and beyond in Life Sciences education'.
46th joint IUBMB-FEBS-PABMB Congress Education Activities
FEBS Education Committee organised its traditional special and poster sessions jointly with IUBMB and an education plenary jointly with the Congress Organisers, at the 46th joint IUBMB-FEBS-PABMB Congress.
1) FEBS/IUBMB Special Session on Education entitled ‘Where do we go from here? Experiences, lessons learned and projections for hybrid post-Covid education’ with speakers from Spain, Australia and the UK.
2) Education Plenary lecture entitled ‘Beating to a different drum: how can education become relevant again?’ by Boris Jokic (Croatia)
3) Poster Session on Education – 22 posters were submitted on education.
4) FEBS Special Session on Research and Career Skills, organised with the FEBS Working Group on the Careers of Young Scientists.

Contribution to FEBS Network
Several posts were published on the FEBS Network Educator channel in 2022, including:
- ‘Decreasing fear of failure and increasing meaningful interactions with students’
- ‘Integrating Augmented Reality into bioscience education’
- ‘Stepping outside of the catch-22 – tips for bioscientists committed to education’
- ‘Gain recognition for your innovations using digital tools in science education’
- ‘Using Pebblepad for e-portfolios in the medical sciences’
- ‘Visual asynchronous learning materials: examples from Edpuzzle and ThingLink’
- ‘Transferable skills education in the biosciences: preparing our graduates for life outside university’

Education Committee Workshops
FEBS Education Joint Workshop with HDBMB (Croatian society) held in October 2022 in Zagreb, Croatia, with the title ‘Designing Educational Research’.
FEBS Education Committee also sponsored an education workshop organised by the Tunisian Education Ambassador, Hatem Fakhfakh, entitled ‘Educational Considerations for Training’ on 7 December 2022.

Contributions to the 2022 IUBMB-FEBS-PABMB Young Scientists’ Forum
The Education Committee participated in two practical sessions of the 2022 IUBMB-FEBS-PABMB Young Scientists’ Forum (held in Vimeiro, Portugal prior to the joint Congress), entitled ‘Career Skills – Practical Exercises’.

Contributions to FEBS Advanced Courses
FEBS Education Committee chair gave a training lecture on the science and art of writing a scientific article at the FEBS Advanced Course ‘Redox Alterations and Cellular Responses: From Signalling to Interventions’, 19-25 September 2022 Spetses island, Greece.
Two workshops (on how to write a scientific paper and how to present your work) were carried on at the FEBS Advanced Course ’360° Lysosome: from Structure to Genomics, from Function to Disease, 4 – 9 October 2022 Kusadasi / Izmir, Turkey.

Integration
The Working Group on Integration (WGI), which was chaired in 2022 by Prof. Jerka Dumić, continued its outreach and support for scientists in European countries with economic challenges and/or no existing or active biochemical society, as well as activities for integration and collaboration between all FEBS societies.

Activities of the WGI during 2022 included:
- working with the FEBS Fellowships Committee on the Collaborative Developmental Scholarships criteria for the exclusive benefit of PhD students in certain FEBS countries with HINARI (Research4Life) status;
- supporting the three societies of Estonia, Latvia and Lithuania with their organisation of joint meetings, with their next meeting held in Tallinn, Estonia in June 2022;
- launch of the Member Society Representatives (MSRs) initiative: commencing in July 2022, this initiative involves one MSR from each FEBS member society to be the main link between their society and FEBS to
strengthen the relationship, as well as providing a voice to keep FEBS informed and the opportunity to network with the other MSRs via a dedicated FEBS Network channel, in online meetings and in person at the annual MSRs meeting held in conjunction with the FEBS Congress. 2022 was the first pilot year of this initiative. FEBS provided limited support to each MSR for them to attend the Congress. All member societies (except the suspended Russia and Belarus) have now nominated MSRs and 30 of the 37 MSRs attended the Congress in Lisbon and MSRs meeting.

- the WGI Chair attended the FEBS-IUBMB-ENABLE kick-off meeting in Cologne, Germany in May 2022 and the Education Committee meeting and Education Ambassadors meeting in Izmir, Türkiye in May 2022.
- the WGI Chair actively led on new initiatives to increase collaboration and engagement with FEBS member societies and collaborated with other committees and working groups.

As part of the WGI activities and the FEBS Congress, financial support was given under the 'Sprinzl Scheme' with a 50% registration fee discount to scientists resident (studying/working) in Armenia, Bosnia and Herzegovina, Georgia, Moldova, Morocco, Serbia, Tunisia and Ukraine to attend the 2022 Congress.

Women in Science
The planned activities of the Working Group on Women in Science (WISE) with Prof. Cecilia Arraiano as Chairperson in 2022, were as follows:
The FEBS/EMBO Women in Science Award, now in its fifteenth year, recognises and rewards the exceptional achievements of a female researcher in molecular biology giving particular attention to the previous five years. Winners of the award are role models who inspire future generations of women in science.
The 15th meeting of the FEBS/EMBO Women in Science Award Committee took place in February 2022 to review the nominations received for the FEBS/EMBO Women in Science Award 2022. Many of the candidates' CVs were excellent. After discussion, the working group voted to award the 2022 prize to Prof. Erin Schuman (Frankfurt, Germany), for her exceptional contributions to our understanding of neuronal cell biology. The award was presented during the FEBS/EMBO Women in Science Award lecture at the IUBMB-FEBS-PABMB Congress, held in Lisbon, Portugal in July 2022.

The working group also planned the following events at the Congress:
- a) the FEBS Special Session on 'Gender Issues in Science' with four invited speakers and an open discussion.
- b) the networking lunch for 50 Congress participants to discuss Women in Science issues.

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

The overall objective of FEBS is to contribute to and promote the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines. As indicated by the specific key objectives of FEBS set out above under 'Objectives', FEBS does this particularly through:
- funding forums for presentation and discussion of research results and related areas of interest at its large annual Congress, Young Scientists' Forum (YSF), FEBS Fellows Meeting, Special Meetings and other Advanced Courses; promoting training through lectures courses, workshops and practical courses of its Advanced Courses programme, as well as its education workshops; and supporting participation of promising young scientists in these events through YSF awards, Youth Travel Fund grants and Congress bursaries;
- facilitating and supporting the exchange of scientific information between biochemists and molecular biologists especially in Europe and other countries of FEBS Constituent Societies principally through these forums and mechanisms, but also through Constituent Society meetings (National Lecture scheme), FEBS3 meetings, FEBS Fellowships (which promote mobility), and schemes to support integration of bioscientists working in economically disadvantaged countries of the FEBS area;
- providing stipends through its Fellowships programme to allow research to be carried out in host laboratories by talented early-career scientists;
- offering high-quality publication of research findings for both authors and readers through its four international molecular life science journals.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES’ REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Through the many activities of FEBS outlined above, the beneficiaries of FEBS include scientists at all levels directly engaged in research and education in the molecular life sciences, and ultimately humankind across the globe through the contributions of these areas of science to human health, agriculture, biotechnology and related areas, and enrichment of human knowledge.

FEBS wholly owns its international journals, which are of importance to FEBS both by directly contributing to its objectives and as a source of income to support its other purposes. FEBS follows all directives on Open Access publishing from the UK, EU and relevant research funders across the world. Two of the FEBS publications – FEBS Open Bio and Molecular Oncology – are fully open access. Its two hybrid journals – The FEBS Journal and FEBS Letters – offer authors open access options, often with no direct cost to authors at institutions with a transformational agreement. In addition, authors are able to deposit accepted research articles, as required by funders, in institutional repositories, through which they are accessible to the public, and all published articles in our hybrid journals are freely available after 12 months to all readers.

FEBS events are normally open to scientists throughout the world. Recipients of FEBS grants for fellowships and for support of participation in meetings are normally required to be members of FEBS’ Constituent Societies (where membership criteria are those expected of learned societies) and resident within the FEBS area of Europe and neighbouring countries. Some FEBS programs particularly benefit disadvantaged scientists.

The trustees confirm that they have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the organisation’s aims and objectives and in planning future activities.

Grant Making Policy
The overall objective of FEBS is to contribute to and promote the advancement of research and education for the public benefit in the molecular life sciences and related disciplines. Policies for key grants awarded by FEBS to achieve these goals are outlined below.

Fellowships
As part of our commitment to young scientists under the FEBS Fellowship program set up in 1978, and to further research in the molecular life sciences, we offer Short-Term Fellowships to members of Constituent Societies, as well as Summer Fellowships to promising Masters/PhD students. The new FEBS Excellence Award program was launched in 2021. It is intended for early-career scientists who have been PIs in their Host Institution for at least one year and are in a salaried capacity. As part of our Fellowships program, we also offer scholarships designed exclusively for members of our Constituent Societies based in FEBS countries with HINARI (Research4Life) status. Our Fellowships are intended to allow members of our Constituent Societies working in a FEBS country to work in a laboratory in another FEBS country.

Eligibility criteria for FEBS Fellowships are set out in detailed guidelines on the FEBS website. The initial applications for Fellowships are assessed on merit by the FEBS Fellowships Committee. Within three months of completion of all Fellowships, awardees are required to prepare a final report on the work carried out during the tenure of the Fellowship. Similarly, Excellence Awardees are asked to provide both a scientific and a financial report to be eligible for the 2nd and 3rd instalments.

Grants for organising FEBS Advanced Courses
Grants for organising FEBS Advanced Courses (including lecture courses, workshops, practical courses and special meetings) are awarded to senior scientists by the FEBS Advanced Courses Committee on a competitive basis. Reports (including scientific and financial) from the organisers are required within 3 months after the event.

Grants for young scientists attending Advanced Courses
Students participating in FEBS Advanced Courses (including lecture courses, workshops and practical courses) may apply for financial support through the FEBS Youth Travel Fund (YTF). In 2022, grants were made to persons travelling from their current country of residence to another country, mostly in the European area.
Applicants for these grants should normally be registered as a student at an institution of higher learning in a country where there is a FEBS Constituent Society or be within five years of having completed a PhD thesis, be a member of a FEBS Constituent Society, and not have received a grant from the Youth Travel Fund to attend an Advanced Course in the current or preceding year or received a grant to attend the Young Scientists’ Forum in the current year. Candidates are shortlisted by the Course organisers on merit.

Grants for organising the FEBS Congress and FEBS3+ meetings, and requests for National Lecture support
FEBS evaluates bids for organising its yearly Congresses and also FEBS3+ meetings, as well as requests from Constituent Societies for National Lecture support, according to their quality; the administrative responsibility for these is in the hands of the FEBS Congress Counsellor (Prof. Miguel A. De la Rosa in 2022).

Grants for attending the FEBS Young Scientists’ Forum and Congress (YSF awards)
Recipients of YSF awards are selected by the Chair of the Working Group on the Careers of Young Scientists (Irene Diaz-Moreno in 2022) and the local organising committee on merit, with eligibility criteria that normally include: i) being a PhD student or postdoctoral fellow within 5 years of finishing his/her PhD at an institution of higher education in a country where there is a FEBS constituent Society; ii) being under 35 years old; iii) being a member of a FEBS Constituent Society; not having attended a recent YSF, and not having received a Youth Travel Fund award in the same year.

Congress bursaries
Recipients of bursaries (which offer financial support with registration, travel and accommodation costs for the Congress) are selected by the host society of that year’s Congress on merit, with eligibility criteria similar to those for YTF and YSF awards.
Achievement and performance

This section summarises and assesses our principal achievements in 2022 against the formal objectives of FEBS. More details of the activities included in brief here can be found in the 'Activities' section above.

Objective 1: holding and arranging congresses, training and educational courses on matters connected with biochemistry and molecular biology and related disciplines

<table>
<thead>
<tr>
<th>Achievements</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FEBS Advanced Courses</strong></td>
<td>In 2022, FEBS continued to fund several Advanced Courses with high scientific content and also funded YTF grants to allow participation of young researchers at the FEBS courses.</td>
</tr>
<tr>
<td>25 FEBS-supported events were planned for 2022: 3 Practical Courses, 8 Advanced Lecture Courses and 8 Workshops, 7 joint FEBS-EMBO Lecture Courses, 2 Practical and Lecture Courses were held as personal events during 2022.</td>
<td></td>
</tr>
<tr>
<td>The assessment procedure for course selection and funding refined, online database for applications and reporting enhanced, FEBS-owned and branded course websites introduced and collaborations with EMBO and IUBMB continued.</td>
<td></td>
</tr>
<tr>
<td><strong>FEB33+ Meetings:</strong></td>
<td>Support for scientists in Estonia, Latvia, Lithuania, Netherlands, Spain and the UK; enhanced links between these FEBS Constituent Societies. See ‘Support for Constituent Society events’ section for more details.</td>
</tr>
<tr>
<td>• Alicante, Spain May 2022: the ‘Machines on Genes’ meeting hosted by the Biochemical Society (UK), in conjunction with the member societies of the Netherlands and Spain;</td>
<td></td>
</tr>
<tr>
<td>• Tallinn, Estonia, June 2022: the Baltic Meeting hosted by the Estonian Biochemical Society, in conjunction with the member societies of Latvia and Lithuania.</td>
<td></td>
</tr>
<tr>
<td>Each meeting received support comprising €10,000 to the host society for general meeting organization and €10,000 to support the attendance of young scientists from the two other participating societies.</td>
<td></td>
</tr>
<tr>
<td><strong>21st Young Scientists Forum (YSF) and 46th FEBS Congress:</strong></td>
<td>The YSF includes over 100 PhD students and young postdocs, whose attendance at this and the Congress is funded by FEBS YSF awards. In addition, FEBS supports participation of a large number of young scientists in its annual Congress through the FEBS Bursaries scheme.</td>
</tr>
<tr>
<td>The 21st Young Scientists’ Forum, in conjunction with IUBMB and FEBS, took place.</td>
<td></td>
</tr>
<tr>
<td>The 46th Congress was held in Lisbon, Portugal in July 2022, in conjunction with IUBMB and PABMB.</td>
<td></td>
</tr>
<tr>
<td>The annual FEBS Congress provides a platform for international scientific exchange and showcases the newest developments in biochemistry, molecular biology and related areas. The Congress comprises plenary lectures, symposia, poster sessions, workshops and other activities on related topics. The Congress is held in countries with a Constituent Society of FEBS.</td>
<td></td>
</tr>
</tbody>
</table>
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES  
(A Company Limited by Guarantee)  

TRUSTEES’ REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2022

Objective 2: facilitating and supporting the exchange of scientific information between biochemists, molecular biologists and scientists working in related disciplines generally and especially in Europe and other countries of Constituent Societies

<table>
<thead>
<tr>
<th>Achievements</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEBS Congress, Advanced Courses and Education Workshops</td>
<td>See above</td>
</tr>
<tr>
<td>Lecturers for Constituent Society and other scientific meetings</td>
<td>Effective enhancement of regional, national and international meetings by funding of distinguished speakers.</td>
</tr>
<tr>
<td>National Lectures awarded to national meetings of the member societies from Croatia, Cyprus, Finland, France, Italy, Latvia, Spain, Sweden, Tunisia and Turkey.</td>
<td></td>
</tr>
<tr>
<td>Other meeting sponsorship</td>
<td>Eminent speakers for special events and meetings beyond Europe, which also allowed collaboration with international organizations and yielded FEBS journals' promotion.</td>
</tr>
<tr>
<td>The Gordon Research Conference USA in 2022.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Achievements</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEBS Fellowships</td>
<td>Promotion of exchange of skills/knowledge.</td>
</tr>
<tr>
<td>Fellows move to work in host lab in different country (see Objective 3 below).</td>
<td></td>
</tr>
<tr>
<td>WGI schemes</td>
<td>Contributes to developing/maintaining pool of effective researchers in Europe.</td>
</tr>
<tr>
<td>Support for communities of molecular life scientists in European countries with economic challenges and/or no existing or active biochemical society through visits, the Congress ‘Spring’ Scheme, Education Workshops and CDS Fellowships as well as encouraging the establishment of new societies and for them to benefit from FEBS.</td>
<td></td>
</tr>
</tbody>
</table>

Objective 3: facilitating and supporting the training of young scientists in research, in the form of fellowships

<table>
<thead>
<tr>
<th>Achievements</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-Term Fellowships</td>
<td>Enhances research possibilities for young scientists; numbers awarded in accordance with budgetary limits.</td>
</tr>
<tr>
<td>22 Short-Term and 10 Summer Fellowships taken up.</td>
<td></td>
</tr>
<tr>
<td>Long – Term Fellowships</td>
<td>Very competitive - only the most outstanding scientists successful; numbers awarded in accordance with budgetary limits. Accounts for major part of FEBS expenditure. This program was discontinued as of 2021.</td>
</tr>
<tr>
<td>5 Long-Term in post.</td>
<td></td>
</tr>
<tr>
<td>Excellence Award</td>
<td>Very competitive - only the most outstanding scientists successful; must be recognized scientists in their field and should possess an outstanding track record.</td>
</tr>
<tr>
<td>19 in post.</td>
<td></td>
</tr>
<tr>
<td>Fellows Meeting</td>
<td>Participants are invited to participate. No selection procedure applies as only current and past FEBS Long-Term Fellows are eligible. The organization costs are shared with the YSF.</td>
</tr>
<tr>
<td>held in Vimeiro, Portugal July 2022 in conjunction with the Young Scientists Forum</td>
<td>17 current and former LTFs accepted the invitation.</td>
</tr>
</tbody>
</table>
Objective 4: organising the editing and publication of scientific research and educational material in biochemistry and molecular biology and related disciplines

<table>
<thead>
<tr>
<th>Achievements</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our journals continue to maintain high standards of peer review. Sixty-one per cent of all articles published were open access (gold OA).</td>
<td>Strong performance of FEBS journals in a challenging scientific publishing environment.</td>
</tr>
</tbody>
</table>

The current Publishing Agreement between FEBS and Wiley runs 2016-2023. The eight-year contract is based on revenue share, guaranteed income and special support for the FEBS Network.

FINANCIAL REVIEW

Journal income and costs
Total income from royalties in 2022 was 0.2% higher than the royalty income in 2021. The total costs for the four FEBS journals, FEBS Journal, FEBS Letters, FEBS Open Bio and Molecular Oncology increased by 13% in 2022 from 2021 (excluding foreign exchange). These costs are the direct costs and support costs including employees who work on the journals. The increase is due mainly to an increase in journal payroll costs.

Distribution of expenditure on FEBS activities
In 2022, Fellowships remained by far the highest area of charitable FEBS spending ~€894,000 (~€817,000 in 2021) then Advanced Courses, gross course grants and YTFs totaling ~€506,000, (~97,000 in 2021). Prizes and awards for excellence in molecular life sciences totaled ~€39,000 (~€30,000 in 2021), and funding of lecturers for meetings within and outside of Europe totaled ~€54,000 (~€20,000 in 2021) including two FEBS 3+ meetings. Several other areas of FEBS work including education workshops, science and society sessions, and ‘integration’ initiatives, were undertaken for ~€78,000 (~€16,000 in 2021) in total.

Governance and support costs
The senior scientists who serve as FEBS Officers and members of FEBS committees all work pro bono, and the holders of key positions in the FEBS Executive Committee generously devote considerable time and energy to FEBS activities. There are a small number of support personnel working in (1) the FEBS Central Administration Office dealing with central administration and communications, (2) the FEBS Treasury Office dealing with financial matters, and (3) those working with the Fellowships and Advanced Courses Committee Chairs to support their work and those of the committees.

The total governance costs - including the expenses associated with higher-level committees (Council, Executive and Finance) within FEBS, Central Administration Office, The Treasury Office and Secretary General expenses, as well as auditor and other fees - amounted to 18% (23% in 2021) of the size of charitable spending in 2022 (note that these governance costs are not included in the total for charitable spending).

An indication of the support costs involved in running the two activities of FEBS with the highest expenditure can be given by the committee expenses as a percentage of the charitable spending in that area; this was approximately 7% in 2022 (4% in 2021) for Fellowships, and 11% in 2022 (20% in 2021) for Advanced Courses (although these figures exclude governance costs of central administration at the FEBS Treasury Office).

Support costs for the journals are covered in 'Journal income and costs' above.

Investment performance
In 2016 FEBS reviewed its investments and the Finance Committee decided to hold a tender for the management of the investments of FEBS. JP Morgan was the successful tenderer after an intensive selection process. The tender was conducted by the Finance Committee, plus the Chair of the Fellowship Committee, with the assistance of an independent investment consultant. By 31 December 2017 the investment portfolio had been moved to JP Morgan. For the twelve months to the 31 December 2022 the investment portfolio held at JP Morgan had a return of -13.09% loss (+14.6% in 2021).
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES’ REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

PRINCIPAL RISKS AND UNCERTAINTIES

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

Change to Journal Income

In addition to directly fulfilling one of the charitable objectives of FEBS (promoting and disseminating scientific research and ideas), our journals provide a source of income to fund FEBS’ other charitable work. Future income streams are uncertain due to major changes in the publishing sector. The income from journal publishing is changing as library contracts move from subscriptions to open access publication fees or other publishing models.

FEBS is addressing these concerns by (1) its policy on reserves (see below) so that some future income can be derived from investments and (2) its negotiated long-term contract with a commercial publisher which, in turn, is negotiating deals with library and funding consortia for Read and Publish / Publish and Read access to the FEBS press journals. A group of funders called cOAlington S mainly from Europe, announced an initiative (called Plan S) in September 2018 requiring their grant holders to publish only in full open access journals from 2021. From 2024 all publication income will transition towards full Open Access. The FEBS Publications Committee has reviewed its consequences and made a strategic plan on how journals can adapt to new publishing requirements of Plan S supported authors.

Return from investments

Up until the end of 2017 FEBS followed a standard investment policy with investment in 30% bonds and 70% equities. Since moving the investment management to JP Morgan, FEBS has made some changes to its policy with investments currently (31 May 2023) allocated to 60% equities, 27% fixed income and cash and 13% alternatives (PE is limited to 8%). The performance of FEBS’ investments is monitored regularly. The performance of the portfolio held at JPM for the year ending 31 December 2022 was -13.09% (+14.6% in 2021). All decisions about investments are made by the Finance Committee, as delegated by the Executive Committee. On occasion the Finance Committee may seek further approval from the Executive Committee on significant investment commitments.

Internal Controls

FEBS has an environment where improvements to the systems and processes are encouraged. The Finance Committee is responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position and to enable them to ensure that the financial statements comply with all statutes and regulations. FEBS’ controls include regular internal and external oversight and checks. Controls and procedures are appropriate for the organisation’s size and operation. FEBS uses automated accounting software from a large, reputable supplier and The Treasury department has several processes to ensure the appropriate use of funds, the management of the accounts and recording of all transactions. Duties within the Treasury are separated, and robust systems of oversight and authorisation are in place.

Impact on overall objectives

The success of FEBS in promoting the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines is carefully monitored by stringent peer review and other methods.

PLANS FOR THE FUTURE

Reserves policy

The total value of funds held by FEBS at 31 December 2022 was €89.3M (€99.2M in 2021). None of the funds were restricted funds or unavailable for the general purposes of the charity at the end of the reporting period and no material amounts have been designated or are otherwise committed as at the end of the reporting period.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

TRUSTEES’ REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

As at year end 2022, approximately 83% could be realised in fewer than 3 days, 9% was in investments that may be realised in 10 years and the rest had varying timescales, up to 4 months, in which the assets may be realised. The investments in private equity and infrastructure cannot be liquidated. These investments will be held for up to 10 years and up to 8% will be held in private equity and infrastructure in FEBS’ main portfolio.

The Treasurer of FEBS’ regularly reviews the performance of FEBS investments during the year. Significant changes in investments and the treatment of funds are discussed and approved by the FEBS Finance Committee and where appropriate, are submitted for further approval from the FEBS Executive Committee.

The FEBS’ reserves policy allocates £4M for one year’s essential funding and this is held in cash at the bank.

The FEBS Trustees have approved the enhancement of the investment portfolio to reach a value that may generate funds to offset potential changes in income due to the new publishing model. The income from the portfolio in addition to royalty income will ensure that FEBS exists in perpetuity providing funding for the running of the journals and its other charitable activities.

Impact of COVID-19
In the short to medium term COVID-19 will not have an impact on the major source of FEBS’ income which is the royalties from FEBS’ journals. The financial performance of the investment portfolio gave an investment performance of 14.6% in 2021. World events including the invasion of Ukraine by Russia, have had a negative impact on FEBS investments 2022, with a fall of 13% in the value of FEBS’ main portfolio.

FEBS did not incur any additional costs due to COVID 19 and its day-to-day operations were carried on without a major impact. No employees of FEBS were furloughed and no government grants were sought or received by FEBS in relation to COVID-19. One of FEBS charitable aims is to support life sciences through its events and in 2021 these activities were curtailed, as they were in 2020. In these cases, the grants have not been paid were rolled over to fund activities in 2022. As a result, expenditure for 2022 is higher due to the number of events postponed from 2020 and 2021.

Future commitments and plans for other areas of FEBS work
We now have firm arrangements for a programme of Annual Congresses until 2024, as these involve substantial forward planning. Expenditure on Advanced Courses up to 2024 and the costs of the FEBS Excellence Awards are included in our budgets.

With regard to future activities, we are also continuing to forge closer links with related European and worldwide organisations that cover contiguous/overlapping areas of molecular life sciences (e.g. biophysics, microbiology, immunology, cancer) with the aim of maximising the use of our impacts and resources.

Concluding Comments
FEBS has continued to operate successfully in promoting the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines, and its current strategy for its long-term survival is progressing smoothly and according to plan. By making provisions with its reserves FEBS will be in a position to provide support to many researchers in years to come.

Approved by order of the members of the board of Trustees and signed on their behalf by:

M De La Rosa
Trustee
Date: 31 August 2023
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

[Signature]

M De La Rosa
Trustee

Date: 31 August 2023
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

OPINION

We have audited the financial statements of The Federation of European Biochemical Societies (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.
OTHER INFORMATION

The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The Trustees are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' Report has been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' Report and from the requirement to prepare a Strategic Report.
RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees’ Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS’ RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors’ Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We obtained an understanding of the legal and regulatory frameworks through our accumulated knowledge and consideration of sector information that is applicable to the charitable company. We determined that the most significant which are directly relevant to specific assertions in the financial statements are those related to the financial reporting framework including but not limited to United Kingdom Generally Accepted Accounting Practice, the Charities Act 2011, Charities SORP, the Companies Act 2006, Data Protection Act 2018 and tax legislation.

- We obtained an understanding of the procedures and controls over the charitable company’s operations and discussed these with those charged with governance. No matters of fraud were brought to our attention during that discussion.

- During our discussions with management, they assessed these as being the normal risks required to be considered by us as auditors by the Auditing Standards (such as management override and revenue recognition) but confirmed that no irregularities here occurred. This was confirmed by our review of management meetings, auditing management override through journal testing, and other adjustments to consider appropriateness, review of the financial statements to ensure no unusual and / or inexplicable variances and general discussions with management during the course of the audit. We did not identify any significant business transactions outside the normal course of the business operations.

- Our senior statutory auditor has assessed that the audit team possessed the ability and competence to identify and recognise non-compliance with the relevant laws and regulations central to the operation of this charitable company. We have not identified any additional laws and regulations which are central to the entity’s operations and which we were not notified about, during the course of our audit fieldwork.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (CONTINUED)

We believe that our audit was capable of detecting material irregularities, including fraud, and our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors’ Report.

USE OF OUR REPORT

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an Auditors’ Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

[Signature]
Mark Murray BCom ACA FCCA (Senior Statutory Auditor)
for and on behalf of
Hill Wooldridge & Co. Limited
107 Hindes Road
Harrow
Middlesex
HA1 1RU
Date: 31 August 2023
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES  
(A Company Limited by Guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 31 DECEMBER 2022

<table>
<thead>
<tr>
<th>Note</th>
<th>Unrestricted funds 2022</th>
<th>Total funds 2022</th>
<th>-Total funds 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Donations</td>
<td>3 6,660</td>
<td>6,660</td>
<td>8,044</td>
</tr>
<tr>
<td>Charitable activities</td>
<td>4 7,170,000</td>
<td>7,170,000</td>
<td>7,156,235</td>
</tr>
<tr>
<td>Investments</td>
<td>5 930,724</td>
<td>930,724</td>
<td>749,092</td>
</tr>
<tr>
<td>Other income</td>
<td>6 56,936</td>
<td>56,936</td>
<td>12,260</td>
</tr>
<tr>
<td><strong>TOTAL INCOME</strong></td>
<td><strong>8,164,320</strong></td>
<td><strong>8,164,320</strong></td>
<td><strong>7,925,631</strong></td>
</tr>
<tr>
<td>Raising funds</td>
<td>7 531,513</td>
<td>531,513</td>
<td>462,734</td>
</tr>
<tr>
<td>Charitable activities</td>
<td>8 6,558,091</td>
<td>6,558,091</td>
<td>3,243,527</td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURE</strong></td>
<td><strong>7,089,604</strong></td>
<td><strong>7,089,604</strong></td>
<td><strong>3,706,261</strong></td>
</tr>
<tr>
<td><strong>NET INCOME BEFORE NET GAINS ON INVESTMENTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net (loss)/gain on investments</td>
<td>(10,964,737)</td>
<td>(10,964,737)</td>
<td>12,241,697</td>
</tr>
<tr>
<td><strong>NET MOVEMENT IN FUNDS</strong></td>
<td>(9,890,021)</td>
<td>(9,890,021)</td>
<td>16,461,067</td>
</tr>
<tr>
<td><strong>RECONCILIATION OF FUNDS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total funds brought forward</td>
<td>99,178,699</td>
<td>99,178,699</td>
<td>82,717,632</td>
</tr>
<tr>
<td>Net movement in funds</td>
<td>(9,890,021)</td>
<td>(9,890,021)</td>
<td>16,461,067</td>
</tr>
<tr>
<td><strong>TOTAL FUNDS CARRIED FORWARD</strong></td>
<td><strong>89,288,678</strong></td>
<td><strong>89,288,678</strong></td>
<td><strong>99,178,699</strong></td>
</tr>
</tbody>
</table>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 25 to 44 form part of these financial statements.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES  
(A Company Limited by Guarantee)  
REGISTERED NUMBER: 08239097

BALANCE SHEET  
AS AT 31 DECEMBER 2022

<table>
<thead>
<tr>
<th>Note</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>FIXED ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tangible assets</td>
<td>12</td>
<td>63,507</td>
</tr>
<tr>
<td>Investments</td>
<td>13</td>
<td>83,177,926</td>
</tr>
<tr>
<td>Social investments</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>83,241,433</td>
</tr>
<tr>
<td>CURRENT ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors</td>
<td>15</td>
<td>358,895</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>6,332,321</td>
<td>7,130,070</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,691,216</td>
</tr>
<tr>
<td>Creditors: amounts falling due within one year</td>
<td>16</td>
<td>(643,971)</td>
</tr>
<tr>
<td>NET CURRENT ASSETS</td>
<td></td>
<td>6,047,245</td>
</tr>
<tr>
<td>TOTAL NET ASSETS</td>
<td></td>
<td>89,288,678</td>
</tr>
<tr>
<td>CHARITY FUNDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted funds</td>
<td>18</td>
<td>89,288,678</td>
</tr>
<tr>
<td>TOTAL FUNDS</td>
<td></td>
<td>89,288,678</td>
</tr>
</tbody>
</table>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

F. Michelangeli Trustee  
Date: 31 August 2023

The notes on pages 25 to 44 form part of these financial statements.
## THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

(A Company Limited by Guarantee)

### STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022

<table>
<thead>
<tr>
<th>Note</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net cash used in operating activities</td>
<td>20</td>
<td>307,105</td>
</tr>
</tbody>
</table>

| **CASH FLOWS FROM INVESTING ACTIVITIES** |       |       |
| Dividends, interests and rents from investments | | 930,724 | 749,092 |
| Purchase of social investment | | - | (72,129) |
| Repayment of social investment | | 72,129 | - |
| Proceeds from sale of investments | | 31,539,222 | 60,940,844 |
| Purchase of investments | | (33,646,929) | (63,467,550) |

| **NET CASH USED IN INVESTING ACTIVITIES** |       |       |
| | | (1,104,854) | (1,849,743) |

| **CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR** |       |       |
| | (797,749) | 1,876,042 |
| Cash and cash equivalents at the beginning of the year | | 7,130,070 | 5,254,028 |

| **CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR** |       |       |
| | 21 | 6,332,321 | 7,130,070 |

The notes on pages 25 to 44 form part of these financial statements.
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and the Companies Act 2006. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Federation of European Biochemical Societies meets the definition of a public benefit entity as defined by FRS 102.

There were no significant estimates or judgements made by management in preparing these financial statements.

The functional and presentational currency is the Euro.

1.2 GOING CONCERN

The Trustees have considered the Company’s forecasts and projections. After making enquiries, the Trustees have concluded that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Therefore, these accounts have been prepared on the going concern basis.

There are no material uncertainties in relation to going concern.

1.3 INCOME

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income from royalties is recognised in line with the period to which it relates.

Income from grants and donations are recognised when the Company has been notified in writing of both the amount and settlement date. In the event that a grant or donation is subject to conditions that require a level of performance before the Company is entitled to the funds, the income is deferred and not recognised until those conditions are fully met, or the fulfillment of those conditions is wholly within the control of the Company and it is probable that those conditions will be fulfilled in the reporting period.

Investment income is recognised in the period in which the Company becomes entitled to the income.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Company; this is normally upon notification of the interest paid or payable by the Bank.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.
1. ACCOUNTING POLICIES (CONTINUED)

1.4 EXPENDITURE

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading. This comprises investment management fees.

Expenditure on charitable activities is incurred directly undertaking the activities which further the Company’s objectives, as well as any associated support costs.

Allocation of costs is based on activity which has driven the relevant cost.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Governance costs are those incurred in connection with administration of the Company and compliance with constitutional and statutory requirements.

1.5 FOREIGN CURRENCIES

Monetary assets and liabilities denominated in foreign currencies are translated into euros at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into euros at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

1.6 TAXATION

The Company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.
1. ACCOUNTING POLICIES (CONTINUED)

1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION (CONTINUED)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following bases:

- Leasehold improvements - over the life of the lease
- Fixtures and fittings - 15% on reducing balance
- Computer equipment and website - 25% on reducing balance

1.8 INVESTMENTS

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

Investments held as fixed assets are shown at cost less provision for impairment.

1.9 SOCIAL INVESTMENTS

Programme related investments are held at fair value if this can be measured reliably. If fair value cannot be measured reliably, they are held at cost less impairment.

1.10 DEBTORS

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 CASH AT BANK AND IN HAND

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 LIABILITIES AND PROVISIONS

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.
1. ACCOUNTING POLICIES (CONTINUED)

1.13 FINANCIAL INSTRUMENTS

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 OPERATING LEASES

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the lease term.

1.15 PENSIONS

The Company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Company to the fund in respect of the year.

1.16 FUND ACCOUNTING

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

2. CRITICAL ACCOUNTING ESTIMATES AND AREAS OF JUDGEMENT

Estimates and judgments are continually evaluated and are based on historical experience and other factors. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

3. INCOME FROM DONATIONS

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>2022</td>
</tr>
<tr>
<td>€</td>
<td>€</td>
</tr>
</tbody>
</table>

Subscriptions receivable

| 6,660 | 6,660 |

Page 28
## 3. INCOME FROM DONATIONS (CONTINUED)

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>€</td>
<td>€</td>
</tr>
</tbody>
</table>

Subscriptions receivable

| 8,044               | 8,044       |

## 4. INCOME FROM CHARITABLE ACTIVITIES

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>2022</td>
</tr>
<tr>
<td>€</td>
<td>€</td>
</tr>
</tbody>
</table>

Royalties receivable

| 7,170,000           | 7,170,000   |

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>€</td>
<td>€</td>
</tr>
</tbody>
</table>

Royalties receivable

| 7,156,235           | 7,156,235   |

## 5. INVESTMENT INCOME

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>2022</td>
</tr>
<tr>
<td>€</td>
<td>€</td>
</tr>
</tbody>
</table>

Franked investment income - dividends

| 608,294             | 608,294     |

Interest received

| 322,430             | 322,430     |

**TOTAL 2022**

| 930,724             | 930,724     |
5. INVESTMENT INCOME (CONTINUED)

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>Franked investment income - dividends</td>
<td>€604,865</td>
<td>€604,865</td>
</tr>
<tr>
<td>Interest received</td>
<td>€144,227</td>
<td>€144,227</td>
</tr>
<tr>
<td><strong>TOTAL 2021</strong></td>
<td><strong>€749,092</strong></td>
<td><strong>€749,092</strong></td>
</tr>
</tbody>
</table>

Investment income from UK investment assets was €198,244 (2021: €131,681). Investment income from investment assets outside the UK was €732,480 (2021: €617,411).

6. OTHER INCOMING RESOURCES

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
<td>2022</td>
</tr>
<tr>
<td>Other income</td>
<td>€56,936</td>
<td>€56,936</td>
</tr>
</tbody>
</table>

Other incoming resources comprise recharges on editorial activities.

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>Other income</td>
<td>€12,260</td>
<td>€12,260</td>
</tr>
</tbody>
</table>

7. INVESTMENT MANAGEMENT COSTS

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
<td>2022</td>
</tr>
<tr>
<td>Portfolio management</td>
<td>€531,513</td>
<td>€531,513</td>
</tr>
</tbody>
</table>
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES  
(A Company Limited by Guarantee)  

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

7. INVESTMENT MANAGEMENT COSTS (CONTINUED)

J.P. Morgan Private Bank, the Company's investment manager, holds a charge over the Company's cash and investments it manages on behalf of the Company.

<table>
<thead>
<tr>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>€</td>
</tr>
<tr>
<td>Portfolio management</td>
<td>462,734</td>
</tr>
</tbody>
</table>

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES

<table>
<thead>
<tr>
<th>Activities undertaken directly</th>
<th>Support and governance costs</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>€</td>
<td>2022</td>
</tr>
<tr>
<td>Journals</td>
<td>363,445</td>
<td>-</td>
</tr>
<tr>
<td>Congress</td>
<td>233,823</td>
<td>250,459</td>
</tr>
<tr>
<td>Fellowships</td>
<td>-</td>
<td>893,743</td>
</tr>
<tr>
<td>Advanced courses</td>
<td>-</td>
<td>506,448</td>
</tr>
<tr>
<td>Other</td>
<td>106,321</td>
<td>86,858</td>
</tr>
<tr>
<td>TOTAL 2022</td>
<td>703,589</td>
<td>1,737,508</td>
</tr>
</tbody>
</table>
## 8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

<table>
<thead>
<tr>
<th>Activities undertaken directly</th>
<th>Grant funding of activities (note 9)</th>
<th>Support and governance costs</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td>Journals</td>
<td>302,688</td>
<td>-</td>
<td>1,129,023</td>
</tr>
<tr>
<td>Congress</td>
<td>110,646</td>
<td>196,798</td>
<td>132,877</td>
</tr>
<tr>
<td>Fellowships</td>
<td>-</td>
<td>816,832</td>
<td>74,983</td>
</tr>
<tr>
<td>Advanced courses</td>
<td>-</td>
<td>97,132</td>
<td>106,860</td>
</tr>
<tr>
<td>Other</td>
<td>9,671</td>
<td>34,653</td>
<td>231,384</td>
</tr>
<tr>
<td><strong>TOTAL 2021</strong></td>
<td><strong>423,005</strong></td>
<td><strong>1,145,415</strong></td>
<td><strong>1,875,107</strong></td>
</tr>
</tbody>
</table>

## ANALYSIS OF DIRECT COSTS

<table>
<thead>
<tr>
<th>Journals</th>
<th>Congress</th>
<th>Other</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2022</strong></td>
<td><strong>2022</strong></td>
<td><strong>2022</strong></td>
<td><strong>2022</strong></td>
</tr>
<tr>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>363,445</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Women in science events</td>
<td>-</td>
<td>11,554</td>
<td>-</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>7,562</td>
<td>38,841</td>
</tr>
<tr>
<td>Science and Society events</td>
<td>-</td>
<td>-</td>
<td>4,868</td>
</tr>
<tr>
<td>National lecture expenses</td>
<td>-</td>
<td>-</td>
<td>5,505</td>
</tr>
<tr>
<td>FEBS Congress</td>
<td>-</td>
<td>79,465</td>
<td>-</td>
</tr>
<tr>
<td>FEBS Young Scientists forum congress</td>
<td>-</td>
<td>130,202</td>
<td>-</td>
</tr>
<tr>
<td>WGI Participation events</td>
<td>-</td>
<td>-</td>
<td>57,107</td>
</tr>
<tr>
<td>Spinzl scheme</td>
<td>-</td>
<td>5,040</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL 2022</strong></td>
<td><strong>363,445</strong></td>
<td><strong>233,823</strong></td>
<td><strong>106,321</strong></td>
</tr>
</tbody>
</table>
8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

ANALYSIS OF DIRECT COSTS (continued)

<table>
<thead>
<tr>
<th></th>
<th>Journals 2021</th>
<th>Congress 2021</th>
<th>Other 2021</th>
<th>Total funds 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>302,688</td>
<td>-</td>
<td>-</td>
<td>302,688</td>
</tr>
<tr>
<td>Women in science events</td>
<td>-</td>
<td>10,014</td>
<td>-</td>
<td>10,014</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>-</td>
<td>1,500</td>
<td>1,500</td>
</tr>
<tr>
<td>Science and Society events</td>
<td>-</td>
<td>-</td>
<td>2,250</td>
<td>2,250</td>
</tr>
<tr>
<td>National lecture expenses</td>
<td>-</td>
<td>-</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>FEBS Congress</td>
<td>-</td>
<td>67,085</td>
<td>-</td>
<td>67,085</td>
</tr>
<tr>
<td>FEBS Young Scientists forum congress</td>
<td>-</td>
<td>30,422</td>
<td>-</td>
<td>30,422</td>
</tr>
<tr>
<td>WGI Participation events</td>
<td>-</td>
<td>-</td>
<td>5,478</td>
<td>5,478</td>
</tr>
<tr>
<td>Spinzl scheme</td>
<td>-</td>
<td>3,125</td>
<td>-</td>
<td>3,125</td>
</tr>
<tr>
<td><strong>TOTAL 2021</strong></td>
<td>302,688</td>
<td>110,646</td>
<td>9,671</td>
<td>423,005</td>
</tr>
</tbody>
</table>

ANALYSIS OF SUPPORT COSTS

<table>
<thead>
<tr>
<th></th>
<th>Journals 2022</th>
<th>Congress 2022</th>
<th>Fellowships 2022</th>
<th>Advanced courses 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>1,123,287</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HR and communications</td>
<td>7,948</td>
<td>61,600</td>
<td>7,948</td>
<td>13,910</td>
</tr>
<tr>
<td>Finance and governance</td>
<td>90,286</td>
<td>90,286</td>
<td>34,395</td>
<td>77,388</td>
</tr>
<tr>
<td>IT &amp; website</td>
<td>6,246</td>
<td>6,248</td>
<td>6,248</td>
<td>6,248</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>-</td>
<td>60,118</td>
<td>56,383</td>
</tr>
<tr>
<td>Foreign exchange losses</td>
<td>1,108,661</td>
<td>221,732</td>
<td>110,866</td>
<td>110,866</td>
</tr>
<tr>
<td><strong>TOTAL 2022</strong></td>
<td>2,336,428</td>
<td>379,866</td>
<td>219,575</td>
<td>264,795</td>
</tr>
</tbody>
</table>
### 8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

#### ANALYSIS OF SUPPORT COSTS (continued)

<table>
<thead>
<tr>
<th></th>
<th>Other 2022</th>
<th>Total funds 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>-</td>
<td>1,123,287</td>
</tr>
<tr>
<td>HR and communications</td>
<td>107,304</td>
<td>198,710</td>
</tr>
<tr>
<td>Finance and governance</td>
<td>137,581</td>
<td>429,936</td>
</tr>
<tr>
<td>IT &amp; website</td>
<td>6,248</td>
<td>31,238</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>116,501</td>
</tr>
<tr>
<td>Foreign exchange losses</td>
<td>665,197</td>
<td>2,217,322</td>
</tr>
</tbody>
</table>

**TOTAL 2022**

<table>
<thead>
<tr>
<th></th>
<th>Journals 2021</th>
<th>Congress 2021</th>
<th>Fellowships 2021</th>
<th>Advanced courses 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>1,014,768</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HR and communications</td>
<td>7,324</td>
<td>56,762</td>
<td>7,323</td>
<td>12,816</td>
</tr>
<tr>
<td>Finance and governance</td>
<td>38,438</td>
<td>38,438</td>
<td>14,643</td>
<td>32,947</td>
</tr>
<tr>
<td>Women in science events</td>
<td>23,849</td>
<td>23,849</td>
<td>11,924</td>
<td>11,924</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>-</td>
<td>34,159</td>
<td>42,259</td>
</tr>
<tr>
<td>National lecture expenses</td>
<td>16,333</td>
<td>8,166</td>
<td>4,083</td>
<td>4,083</td>
</tr>
<tr>
<td>Foreign exchange losses</td>
<td>28,311</td>
<td>5,662</td>
<td>2,831</td>
<td>2,831</td>
</tr>
</tbody>
</table>

**TOTAL 2021**

<table>
<thead>
<tr>
<th></th>
<th>€</th>
<th>€</th>
<th>€</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1,129,023</td>
<td>132,877</td>
<td>74,963</td>
<td>106,860</td>
</tr>
</tbody>
</table>
8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

ANALYSIS OF SUPPORT COSTS (continued)

<table>
<thead>
<tr>
<th></th>
<th>Total funds 2021</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other funds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>€</td>
<td></td>
</tr>
<tr>
<td>Editorial fees and expenses</td>
<td>-</td>
<td>1,014,768</td>
</tr>
<tr>
<td>HR and communications</td>
<td>98,877</td>
<td>183,102</td>
</tr>
<tr>
<td>Finance and governance</td>
<td>58,572</td>
<td>183,038</td>
</tr>
<tr>
<td>Women in science events</td>
<td>7,950</td>
<td>79,496</td>
</tr>
<tr>
<td>Education, fellowship and advanced courses committee events</td>
<td>-</td>
<td>76,418</td>
</tr>
<tr>
<td>National lecture expenses</td>
<td>48,998</td>
<td>81,663</td>
</tr>
<tr>
<td>Foreign exchange losses</td>
<td>16,987</td>
<td>56,622</td>
</tr>
<tr>
<td><strong>TOTAL 2021</strong></td>
<td>231,384</td>
<td>1,675,107</td>
</tr>
</tbody>
</table>

9. ANALYSIS OF GRANTS

<table>
<thead>
<tr>
<th></th>
<th>Grants to Institutions 2022</th>
<th>Grants to Individuals 2022</th>
<th>Total funds 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress</td>
<td>€ 89,426</td>
<td>€ 161,033</td>
<td>€ 250,459</td>
</tr>
<tr>
<td>Fellowships</td>
<td>-</td>
<td>€ 893,743</td>
<td>€ 893,743</td>
</tr>
<tr>
<td>Advanced courses</td>
<td>€ 433,171</td>
<td>€ 73,277</td>
<td>€ 506,448</td>
</tr>
<tr>
<td>Other</td>
<td>€ 48,649</td>
<td>€ 38,209</td>
<td>€ 86,858</td>
</tr>
<tr>
<td><strong>TOTAL 2022</strong></td>
<td>€ 571,246</td>
<td>€ 1,166,262</td>
<td>€ 1,737,508</td>
</tr>
</tbody>
</table>
9. **ANALYSIS OF GRANTS (CONTINUED)**

<table>
<thead>
<tr>
<th></th>
<th>Grants to Institutions 2021 €</th>
<th>Grants to Individuals 2021 €</th>
<th>Total funds 2021 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress</td>
<td>146,125</td>
<td>50,873</td>
<td>196,798</td>
</tr>
<tr>
<td>Fellowships</td>
<td>-</td>
<td>816,832</td>
<td>816,832</td>
</tr>
<tr>
<td>Advanced courses</td>
<td>87,113</td>
<td>10,019</td>
<td>97,132</td>
</tr>
<tr>
<td>Other</td>
<td>25,000</td>
<td>9,653</td>
<td>34,653</td>
</tr>
<tr>
<td><strong>TOTAL 2021</strong></td>
<td><strong>258,238</strong></td>
<td><strong>887,177</strong></td>
<td>1,145,415</td>
</tr>
</tbody>
</table>

The Company has made the following material grants to institutions during the year:

<table>
<thead>
<tr>
<th>Name of Institution</th>
<th>2022 €</th>
<th>2021 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced courses</td>
<td>433,171</td>
<td>87,113</td>
</tr>
<tr>
<td>FEBS Congress Grant</td>
<td>89,426</td>
<td>146,125</td>
</tr>
<tr>
<td>Grants/sponsorship to other organisations/conferences</td>
<td>3,290</td>
<td></td>
</tr>
<tr>
<td>FEBS3+ Grant</td>
<td>40,359</td>
<td>20,000</td>
</tr>
<tr>
<td>Alliance for Biomedical Research Grant</td>
<td>5,000</td>
<td>5,000</td>
</tr>
</tbody>
</table>

**TOTAL** 571,246 258,238

10. **AUDITORS' REMUNERATION**

<table>
<thead>
<tr>
<th></th>
<th>2022 €</th>
<th>2021 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fees payable to the Company's auditor for the audit of the Company's annual accounts</td>
<td>20,650</td>
<td>20,226</td>
</tr>
</tbody>
</table>
11. STAFF COSTS, KEY MANAGEMENT PERSONNEL AND TRUSTEES' REMUNERATION AND EXPENSES

<table>
<thead>
<tr>
<th></th>
<th>As restated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022 (€)</td>
</tr>
<tr>
<td>Wages and salaries</td>
<td>963,723</td>
</tr>
<tr>
<td>Social security costs</td>
<td>155,975</td>
</tr>
<tr>
<td>Other pension costs</td>
<td>99,635</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,219,333</strong></td>
</tr>
</tbody>
</table>

During the year, payments amounting to €3,966 were made to one employee in respect of voluntary redundancy.

The average number of persons employed by the Company during the year was as follows:

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(€)</td>
<td>(€)</td>
</tr>
<tr>
<td>Publications (Cambridge, UK)</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Publications (Heidelberg, Germany)</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Publications (Barcelona, Spain)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Treasury</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Central admin</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>20</strong></td>
<td><strong>18</strong></td>
</tr>
</tbody>
</table>

One employee received remuneration falling within the band €70,000 to €79,999.

The key management personnel of the Company comprises the Trustees. The Trustees all give their time and expertise without any kind of remuneration or other benefit in kind with the exception of the following Trustees who provided services to the Company during the year:
### THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

### NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>M De La Rosa (Editorial services)</td>
<td>25,266</td>
<td>25,216</td>
</tr>
<tr>
<td>I Diaz Moreno (Editorial services)</td>
<td>585</td>
<td>985</td>
</tr>
<tr>
<td>C Arraiano (Editorial services)</td>
<td>200</td>
<td>-</td>
</tr>
<tr>
<td>B Vérerissy (Editorial services)</td>
<td>160</td>
<td>385</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>26,211</td>
<td>26,586</td>
</tr>
</tbody>
</table>

These services are in accordance with the Company's governing document and in accordance with sections 185 to 188 of the Charities Act 2011.

During the year, 12 (2021: 6) Trustees received reimbursement of expenses or had expenses paid directly to a third party on their behalf totalling €35,645 (2021: €2,397).

### Other personnel costs

Due to the wide geographical spread of the Company's activities, some staffing requirements are fulfilled by independent parties and freelancers. Details of the cost and number of personnel contracted in this manner are detailed below

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Copenhagen Journals Administrator</td>
<td>-</td>
<td>20,010</td>
</tr>
<tr>
<td>Fellowship Committee Administrator</td>
<td>28,000</td>
<td>28,000</td>
</tr>
<tr>
<td>Advanced Courses Committee Administrator</td>
<td>26,872</td>
<td>23,549</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>54,872</td>
<td>69,559</td>
</tr>
</tbody>
</table>

The average number of other such personnel (including part-time personnel) engaged by the Company during the period was as follows:

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Copenhagen Journals Administrator</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Fellowship Committee Administrator</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Advanced Courses Committee Administrator</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES  
(A Company Limited by Guarantee) 

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

12. TANGIBLE FIXED ASSETS

<table>
<thead>
<tr>
<th></th>
<th>Leasehold improvements €</th>
<th>Fixtures and fittings €</th>
<th>Computer equipment and website €</th>
<th>Total €</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COST</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 January 2022</td>
<td>59,681</td>
<td>12,390</td>
<td>104,338</td>
<td>176,409</td>
</tr>
<tr>
<td>At 31 December 2022</td>
<td>59,681</td>
<td>12,390</td>
<td>104,338</td>
<td>176,409</td>
</tr>
<tr>
<td><strong>DEPRECIATION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 January 2022</td>
<td>13,217</td>
<td>4,198</td>
<td>82,626</td>
<td>100,041</td>
</tr>
<tr>
<td>Charge for the year</td>
<td>6,204</td>
<td>1,229</td>
<td>5,428</td>
<td>12,861</td>
</tr>
<tr>
<td>At 31 December 2022</td>
<td>19,421</td>
<td>5,427</td>
<td>88,054</td>
<td>112,902</td>
</tr>
<tr>
<td><strong>NET BOOK VALUE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 31 December 2022</td>
<td>40,260</td>
<td>6,963</td>
<td>16,284</td>
<td>63,507</td>
</tr>
<tr>
<td>At 31 December 2021</td>
<td>46,464</td>
<td>8,192</td>
<td>21,712</td>
<td>76,368</td>
</tr>
</tbody>
</table>

13. FIXED ASSET INVESTMENTS

<table>
<thead>
<tr>
<th></th>
<th>Listed investments €</th>
<th>Cash held at broker €</th>
<th>Total €</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VALUATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 January 2022</td>
<td>91,808,846</td>
<td>226,110</td>
<td>92,034,956</td>
</tr>
<tr>
<td>Additions</td>
<td>33,261,786</td>
<td>-</td>
<td>33,261,786</td>
</tr>
<tr>
<td>Disposals (proceeds €31,539,222; realised loss £1,803,208)</td>
<td>(33,342,430)</td>
<td>-</td>
<td>(33,342,430)</td>
</tr>
<tr>
<td>Revaluations</td>
<td>(9,161,529)</td>
<td>-</td>
<td>(9,161,529)</td>
</tr>
<tr>
<td>Cash movement</td>
<td>-</td>
<td>385,143</td>
<td>385,143</td>
</tr>
<tr>
<td><strong>AT 31 DECEMBER 2022</strong></td>
<td>82,566,673</td>
<td>611,253</td>
<td>83,177,926</td>
</tr>
</tbody>
</table>
13. **FIXED ASSET INVESTMENTS (CONTINUED)**

The market value of investment assets in the UK is €10,282,693 (2021: €16,134,970). The market value of investment assets outside the UK is €72,283,980 (2021: €75,673,876).

FEBS seeks to produce the best financial return within an acceptable level of risk. The investments are to enable FEBS to fund its activities in the long-term. The returns on investment are to provide funding of charitable activities and to increase the size of the investment fund in the next 7 – 8 years. The aim is to increase the size of the investment fund to provide higher income in the future to offset any potential reduction in income from royalties. The investment objective is to generate a return of HICP plus 3.5%, over the long term, after expenses. HICP the Harmonised Index of Consumer Prices is to be used as a measure. This should allow FEBS to at least maintain the real value of the assets, whilst funding annual expenditure over time. FEBS has a target level of investment that will cover any shortfall from publications income. FEBS uses a total return investment strategy.

The total net gains on investments as per the Statement of Financial Activities comprises realised losses of €1,803,208 and unrealised losses of €9,161,529.

14. **SOCIAL INVESTMENTS**

<table>
<thead>
<tr>
<th>Programme related investments</th>
<th>€</th>
<th>Total</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 January 2022</td>
<td>72,129</td>
<td>72,129</td>
<td></td>
</tr>
<tr>
<td>Redemption</td>
<td>(72,129)</td>
<td>(72,129)</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The social investment represented a non-interest-bearing loan to fund the Biochemical Global Summit, which took place in Lisbon between 9 and 14 July 2022. The loan was repaid during the year.

15. **DEBTORS**

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Trade debtors</td>
<td>146,393</td>
<td>24,761</td>
</tr>
<tr>
<td>Other debtors</td>
<td>62,154</td>
<td>36,079</td>
</tr>
<tr>
<td>Prepayments and accrued income</td>
<td>150,348</td>
<td>375,812</td>
</tr>
<tr>
<td></td>
<td>358,895</td>
<td>436,652</td>
</tr>
</tbody>
</table>

Page 40
16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade creditors</td>
<td>212,873</td>
<td>121,864</td>
</tr>
<tr>
<td>Other taxation and social security</td>
<td>349,499</td>
<td>363,952</td>
</tr>
<tr>
<td>Other creditors</td>
<td>2,704</td>
<td>405</td>
</tr>
<tr>
<td>Accruals and deferred income</td>
<td>78,895</td>
<td>85,255</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>643,971</strong></td>
<td><strong>571,476</strong></td>
</tr>
</tbody>
</table>

17. PRIOR YEAR ADJUSTMENTS

It has been identified that staff costs relating to employees working in Germany and Spain had been omitted from the staff costs disclosure (note 11). The effect of including these costs is an increase in wages and salaries, social security costs and other pension costs of €388,147, €85,013 and €12,092, respectively. The impact of this omission is confined to note 11 staff costs: the Statement of Financial Activities and Balance Sheet as presented in the prior-year accounts are unaffected.
18. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

<table>
<thead>
<tr>
<th></th>
<th>Balance at 1 January 2022</th>
<th>Income</th>
<th>Expenditure</th>
<th>Gains/(Losses)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>UNRESTRICTED FUNDS</td>
<td>General Funds</td>
<td>99,178,699</td>
<td>8,164,320</td>
<td>(7,089,604)</td>
</tr>
</tbody>
</table>

STATEMENT OF FUNDS - PRIOR YEAR

<table>
<thead>
<tr>
<th></th>
<th>Balance at 1 January 2021</th>
<th>Income</th>
<th>Expenditure</th>
<th>Gains/(Losses)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>UNRESTRICTED FUNDS</td>
<td>General Funds</td>
<td>82,717,632</td>
<td>7,925,631</td>
<td>(3,706,261)</td>
</tr>
</tbody>
</table>

19. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds 2022</th>
<th>Total funds 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>63,507</td>
<td>63,507</td>
</tr>
<tr>
<td>Fixed asset investments</td>
<td>83,177,926</td>
<td>83,177,926</td>
</tr>
<tr>
<td>Current assets</td>
<td>6,691,216</td>
<td>6,691,216</td>
</tr>
<tr>
<td>Creditors due within one year</td>
<td>(643,971)</td>
<td>(643,971)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>89,288,678</td>
<td>89,288,678</td>
</tr>
</tbody>
</table>
19. ANALYSIS OF NET ASSETS BETWEEN FUNDS (CONTINUED)

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted funds</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
<td>2021</td>
</tr>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>76,368</td>
<td>76,368</td>
</tr>
<tr>
<td>Fixed asset investments</td>
<td>92,034,956</td>
<td>92,034,956</td>
</tr>
<tr>
<td>Social investments</td>
<td>72,129</td>
<td>72,129</td>
</tr>
<tr>
<td>Current assets</td>
<td>7,566,722</td>
<td>7,566,722</td>
</tr>
<tr>
<td>Creditors due within one year</td>
<td>(571,476)</td>
<td>(571,476)</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>99,178,699</td>
<td>99,178,699</td>
</tr>
</tbody>
</table>

20. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Net (expenditure)/income for the year (as per Statement of Financial Activities)</td>
<td>(9,890,021)</td>
<td>16,461,067</td>
</tr>
<tr>
<td>ADJUSTMENTS FOR:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation charges</td>
<td>12,861</td>
<td>14,885</td>
</tr>
<tr>
<td>Losses/(gains) on investments</td>
<td>10,964,737</td>
<td>(12,241,697)</td>
</tr>
<tr>
<td>Dividends, interests and rents from investments</td>
<td>(930,724)</td>
<td>(749,092)</td>
</tr>
<tr>
<td>Decrease in debtors</td>
<td>77,757</td>
<td>118,242</td>
</tr>
<tr>
<td>Increase in creditors</td>
<td>72,495</td>
<td>122,380</td>
</tr>
<tr>
<td><strong>NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES</strong></td>
<td>307,105</td>
<td>3,725,785</td>
</tr>
</tbody>
</table>

21. ANALYSIS OF CASH AND CASH EQUIVALENTS

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Cash in hand</td>
<td>6,332,321</td>
<td>7,130,070</td>
</tr>
<tr>
<td><strong>TOTAL CASH AND CASH EQUIVALENTS</strong></td>
<td>6,332,321</td>
<td>7,130,070</td>
</tr>
</tbody>
</table>
22. ANALYSIS OF CHANGES IN NET DEBT

<table>
<thead>
<tr>
<th></th>
<th>At 1 January 2022</th>
<th>Cash flows</th>
<th>At 31 December 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>7,130,070</td>
<td>(797,749)</td>
<td>6,332,321</td>
</tr>
</tbody>
</table>


23. OPERATING LEASE COMMITMENTS

At 31 December 2022 the Company had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Not later than 1 year</td>
<td>55,969</td>
<td>58,967</td>
</tr>
<tr>
<td>Later than 1 year and not later than 5 years</td>
<td>13,992</td>
<td>73,709</td>
</tr>
<tr>
<td></td>
<td>69,961</td>
<td>132,676</td>
</tr>
</tbody>
</table>

24. RELATED PARTY TRANSACTIONS

The Company has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Company at 31 December 2022.
<table>
<thead>
<tr>
<th>Constituent Society</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Österreichische Gesellschaft für Molekulare Biowissenschaften und Biotechnologie (ÖGMBT) Marxbox, VBC, Helmut-Quattinger-Gasse 2, Stiege 02, EG L 01, 1030 Wien Austria <a href="http://www.ogmbt.at">www.ogmbt.at</a></td>
</tr>
<tr>
<td>Belarus - (Associate) suspended</td>
<td>The Belarusian Society of Biochemists and Molecular Scientists (BSSMBM), Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, 50 Lenin Komosomol Boulevard, 230030 Grodno, Belarus.</td>
</tr>
<tr>
<td>Belgium</td>
<td>Société Belge de Biochimie et de Biologie Moleculaire (BMB), Nanobody Lab, Dept. of Biochemistry, Ghent University, Albert Baertsoenkaai 3 9000 Ghent Belgium <a href="http://www.biochemistry.be">www.biochemistry.be</a></td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>Association of Biochemists and Molecular Biologists in Bosnia and Herzegovina (ABMB in B&amp;H) Faculty of Medicine, University of Sarajevo, Čekaluša 90, 71000 Sarajevo, Bosnia and Herzegovina <a href="http://www.ubmbubh.net">www.ubmbubh.net</a></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Bulgarian Biochemical, Biophysical and Molecular Biology Society (BBMBS), Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev st. bl 21, Sofia 1113, Bulgaria <a href="http://www.old.usb.bg/Bg/Sections.htm">www.old.usb.bg/Bg/Sections.htm</a></td>
</tr>
<tr>
<td>Croatia</td>
<td>Croatian Society of Biochemistry and Molecular Biology (HDBMB), Ksavarska cesta 2, HR-10000 Zagreb Croatia <a href="http://www.hdmbmb.hr">www.hdmbmb.hr</a></td>
</tr>
<tr>
<td>Cyprus</td>
<td>BIOC-Society of Biological Sciences in Cyprus (BIOC-SBScy), Department of Biological Sciences, University of Cyprus, 1 University Avenue, Aglandja 2109, Nicosia, Cyprus <a href="https://sbscy.org/">https://sbscy.org/</a></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Czech Society for Biochemistry and Molecular Biology (ČSBMB), Kladsenská 48, CZ-16 000 Prague 6 Czech Republic <a href="http://www.csmb.cz">www.csmb.cz</a></td>
</tr>
<tr>
<td>Denmark</td>
<td>Danish Biochemical Society (Dansk Biokemisk Forening), Unit of Cell Stress and Survival, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark <a href="http://www.biokemi.org/english">www.biokemi.org/english</a></td>
</tr>
<tr>
<td>Estonia</td>
<td>Estonian Biochemical Society (EBS), Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia <a href="http://www.biokemieselts.ee">www.biokemieselts.ee</a></td>
</tr>
<tr>
<td>Finland</td>
<td>Societas Biochimica, Biophysica et Microbiologica Fenniae (Biobio Society), University of Helsinki, Haartmaninkatu 8, 00290 Helsinki Finland <a href="http://www.biobio.org">www.biobio.org</a></td>
</tr>
<tr>
<td>France</td>
<td>Société Francaise de Biochimie et Biologie Moléculaire (SFBBM), IBMC, 15 Rue René Descartes, 67084 Strasbourg Cedex, France <a href="http://www.sfbbm.fr">www.sfbbm.fr</a></td>
</tr>
<tr>
<td>Georgia</td>
<td>Association of Georgian Biochemists (AGB), Institute of Chemical Biology, Ilia State University, 3/5 K.Cholokashvili Av., Tbilisi 0162, Georgia</td>
</tr>
<tr>
<td>Germany</td>
<td>Gesellschaft für Biochemie und Molekularbiologie GBM e.V. (GBM), Mörfelder Landstr. 125 D-60598 Frankfurt/Main, Germany <a href="http://www.gbm-online.de">www.gbm-online.de</a></td>
</tr>
<tr>
<td>Greece</td>
<td>Hellenic Society of Biochemistry and Molecular (HSBMB) 11 Soufliou Street, Athens 115 27 Greece <a href="http://www.eeemb.gr">www.eeemb.gr</a></td>
</tr>
<tr>
<td>Hungary</td>
<td>Hungarian Biochemical Society (Magyar Biokémiai Egyesület – MBKE), Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Magyar tudosok koruja 2, H-1117 Budapest, Hungary <a href="http://www.mbkpegy.hu">www.mbkpegy.hu</a></td>
</tr>
<tr>
<td>Israel</td>
<td>Israel Society for Biochemistry and Molecular Biology (ISBMB), Dept. of Biological Chemistry, The Alexander Silberman Institute of Life Science, The Hebrew University of Jerusalem, Givat Ram Campus, Jerusalem 91904, Israel <a href="http://www.weizmann.ac.il/isbmb">www.weizmann.ac.il/isbmb</a></td>
</tr>
<tr>
<td>Italy</td>
<td>Società Italiana di Biochimica e Biologia Molecolare (SIB), Dip. to di Scienze Biochimie 'A. Rossi Fanelli', Sapienza Università di Roma, P. Ie Aldo Moro 5, 00185 Roma, Italy <a href="http://www.biochimica.it">www.biochimica.it</a></td>
</tr>
<tr>
<td>Latvia</td>
<td>Latvian Biochemical Society (LaBS), Latvian Biomedical Research and Study Centre, Ratsupites Street 1, LV 1067 Riga, Latvia</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Lithuanian Biochemical Society (LBD), Sauletekio al. 7, LT-10223 Vilnius, Lithuania <a href="http://www.biochemistry.lt">www.biochemistry.lt</a></td>
</tr>
<tr>
<td>Country</td>
<td>Institute</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Moldova (Associate)</td>
<td>Moldovan Society of Biochemistry and Molecular Biology (MSBMB), Institute of Genetics, Physiology and Protection of Plants, Academy of Sciences of Moldova, 20 Padurii str., Chisinau, 2002-MD Moldova</td>
</tr>
<tr>
<td>Morocco (Associate)</td>
<td>Moroccan Society of Biochemistry and Molecular Biology (SMBBM), Hassan II University of Casablanca, Laboratory of Sciences, Faculty of Sciences and Techniques, B.P 146 Quartier Yasmine, Mohammedia, Morocco</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>The Netherlands Society for Biochemistry and Molecular Biology (NVBMB), NMR Group, Dept. of Chemistry, Utrecht University, Padualaan 12, 3584 CH Utrecht, The Netherlands <a href="http://www.kncv.nl/nvbmb">www.kncv.nl/nvbmb</a></td>
</tr>
<tr>
<td>Norway</td>
<td>Norwegian Biochemical Society (NBS), NTNU, Fakultet for medisin og helsevitenskap, 7491 Trondheim, Norway <a href="http://www.biokiemisk.com">www.biokiemisk.com</a></td>
</tr>
<tr>
<td>Poland</td>
<td>Polish Biochemical Society (PT Bioch), Nencki Institute of Experimental Biology, 3 Pasteur str. 02-093 Warsaw Poland <a href="http://www.ptbioch.edu.pl">www.ptbioch.edu.pl</a></td>
</tr>
<tr>
<td>Portugal</td>
<td>Portuguese Biochemistry Society (SPB), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal <a href="http://www.spb.pt">www.spb.pt</a></td>
</tr>
<tr>
<td>Romania</td>
<td>Romanian Society of Biochemistry and Molecular Biology (RSBMB), Institute of Biochemistry, Splaiul Independentei 296, sect. 6, 060031 Bucharest, Romania <a href="http://www.srbm.biochim.ro">www.srbm.biochim.ro</a></td>
</tr>
<tr>
<td>Russia - suspended</td>
<td>National Committee of Biochemists and Molecular Biologists (NCBMB) Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia <a href="http://www.rusbiochem.org">www.rusbiochem.org</a></td>
</tr>
<tr>
<td>Serbia</td>
<td>Serbian Biochemical Society (SBS), Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Studentski trg 16, 11000 Belgrade Serbia <a href="http://www.bds.org.rs/en/home.html">www.bds.org.rs/en/home.html</a></td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Society for Biochemistry and Molecular Biology (SSBMB), Dept. of Molecular Biology, Faculty of Science, Charles University in Bratislava, Ilkovicova 6, 842 15 Bratislava Slovak Republic <a href="http://www.ssbmb.sk">www.ssbmb.sk</a></td>
</tr>
<tr>
<td>Slovenia</td>
<td>Slovenian Biochemical Society (SBD), University of Ljubljana, Faculty of Medicine, Vrazov trg 2, SI-1000 Ljubljana, Slovenia <a href="http://www.sbd.si">www.sbd.si</a></td>
</tr>
<tr>
<td>Spain</td>
<td>Sociedad Española de Bioquímica y Biológica Molecular (SEBBM), CIB-CSIC, c/Ramiro de Maetu, 9 E-28040 Madrid, Spain <a href="http://www.sebbm.es">www.sebbm.es</a></td>
</tr>
<tr>
<td>Switzerland</td>
<td>Life Sciences Switzerland (LS2), Swiss Society for Molecular and Cellular Biosciences, MCB section of LS2, Institute of Cell Biology, University of Bern, Switzerland <a href="http://www.ls2.ch">www.ls2.ch</a></td>
</tr>
<tr>
<td>Tunisia (Associate)</td>
<td>The Tunisian Association of Biological Sciences (ATSB; Association Tunisienne des Sciences Biologiques; Dep Biologie - INSAT, Université de Carthage, BP 676 - Centre Urbain Nord, 1080 Tunis cedex, Tunisie <a href="http://www.atsb-bio.org">www.atsb-bio.org</a></td>
</tr>
<tr>
<td>Türkiye</td>
<td>Turkish Biochemical Society (TBS), Ege University, Faculty of Medicine, Dept. of Biochemistry, İzmir, Turkey <a href="http://www.turkiyebiyokimyadernegi.org.tr">www.turkiyebiyokimyadernegi.org.tr</a></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>The Biochemical Society, 1 Naoroji St, London, WC1X 0GB, UK <a href="http://www.biochemistry.org">www.biochemistry.org</a></td>
</tr>
</tbody>
</table>

FEBS had 39 Constituent Societies in 2022, comprising 35 Member Societies and 4 Associate Member Societies.
## APPENDIX 2

<table>
<thead>
<tr>
<th>Member Societies as at 31 December 2022</th>
<th>no. members</th>
<th>Total Subscription</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Association of Armenian Biochemists</td>
<td>120</td>
<td>€ 30.00</td>
</tr>
<tr>
<td>2 Austrian Association of Molecular Life Sciences and Biotechnology (ÖGMBT)</td>
<td>626</td>
<td>€ 156.50</td>
</tr>
<tr>
<td>3 Société Belge de Biochimie et de Biologie Moleculaire</td>
<td>500</td>
<td>€ 125.00</td>
</tr>
<tr>
<td>4 ABMB in Bosnia and Herzegovina</td>
<td>100</td>
<td>€ 25.00</td>
</tr>
<tr>
<td>5 Bulgarian Society for Biochemistry, Biophysics and Molecular Biology</td>
<td>100</td>
<td>€ 25.00</td>
</tr>
<tr>
<td>6 Croatian Society of Biochemistry and Molecular Biology</td>
<td>514</td>
<td>€ 128.50</td>
</tr>
<tr>
<td>7 Society of Biological Sciences in Cyprus</td>
<td>120</td>
<td>€ 30.00</td>
</tr>
<tr>
<td>8 Czech Society for Biochemistry and Molecular Biology</td>
<td>620</td>
<td>€ 155.00</td>
</tr>
<tr>
<td>9 Danish Society for Biochemistry and Molecular Biology</td>
<td>380</td>
<td>€ 95.00</td>
</tr>
<tr>
<td>10 Estonian Biochemical Society</td>
<td>110</td>
<td>€ 27.50</td>
</tr>
<tr>
<td>11 Societas Biochimica, Biophysica et Microbiologica Fenniae</td>
<td>515</td>
<td>€ 128.75</td>
</tr>
<tr>
<td>12 Société Française de Biochimie et de Biologie Moléculaire (SFBBM)</td>
<td>1,300</td>
<td>€ 325.00</td>
</tr>
<tr>
<td>13 Association of Georgian Biochemists</td>
<td>83</td>
<td>€ 20.75</td>
</tr>
<tr>
<td>14 Gesellschaft für Biochemie und Molekularbiologie e.V.</td>
<td>2,870</td>
<td>€ 717.50</td>
</tr>
<tr>
<td>15 Hellenic Society of Biochemistry and Molecular Biology</td>
<td>340</td>
<td>€ 85.00</td>
</tr>
<tr>
<td>16 Hungarian Biochemical Society</td>
<td>800</td>
<td>€ 200.00</td>
</tr>
<tr>
<td>17 Israel Society for Biochemistry and Molecular Biology</td>
<td>41</td>
<td>€ 10.25</td>
</tr>
<tr>
<td>18 Italian Society of Biochemistry and Molecular Biology</td>
<td>1,000</td>
<td>€ 250.00</td>
</tr>
<tr>
<td>19 Latvian Biochemical Society</td>
<td>100</td>
<td>€ 25.00</td>
</tr>
<tr>
<td>20 Lithuanian Biochemical Society</td>
<td>265</td>
<td>€ 66.25</td>
</tr>
<tr>
<td>21 Nederlandse Vereniging voor Biochemie en Moleculaire Biologie</td>
<td>1,067</td>
<td>€ 266.75</td>
</tr>
<tr>
<td>22 Norwegian Biochemical Society</td>
<td>300</td>
<td>€ 75.00</td>
</tr>
<tr>
<td>23 Polish Biochemical Society</td>
<td>1,014</td>
<td>€ 253.50</td>
</tr>
<tr>
<td>24 Portuguese Biochemical Society</td>
<td>350</td>
<td>€ 87.50</td>
</tr>
<tr>
<td>25 Societatea Romana de Biochimie si Biologie Moleculara</td>
<td>280</td>
<td>€ 70.00</td>
</tr>
<tr>
<td>26 Serbian Biochemical Society</td>
<td>180</td>
<td>€ 45.00</td>
</tr>
<tr>
<td>27 Slovak Society for Biochemistry and Molecular Biology</td>
<td>220</td>
<td>€ 55.00</td>
</tr>
<tr>
<td>28 Slovenian Biochemical Society</td>
<td>220</td>
<td>€ 55.00</td>
</tr>
<tr>
<td>29 Sociedad Espanola de Bioquimica y Biologica Molecular</td>
<td>2,911</td>
<td>€ 727.75</td>
</tr>
<tr>
<td>30 Swedish Society for Biochemistry, Biophysics and Molecular Biology</td>
<td>426</td>
<td>€ 106.50</td>
</tr>
<tr>
<td>31 Life Sciences Switzerland (LS2)</td>
<td>947</td>
<td>€ 236.75</td>
</tr>
<tr>
<td>32 Turkish Biochemical Society</td>
<td>600</td>
<td>€ 150.00</td>
</tr>
<tr>
<td>33 Biochemical Society</td>
<td>6,137</td>
<td>€ 1,534.25</td>
</tr>
<tr>
<td>34 Ukrainian Biochemical Society</td>
<td>680</td>
<td>€ 170.00</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>25,836</strong></td>
<td><strong>€ 6,459.00</strong></td>
</tr>
</tbody>
</table>

**ASSOCIATE MEMBERS**

- Moldavian Society of Biochemistry and Molecular Biology (MSBMB)
- Moroccan Society of Biochemistry and Molecular Biology (SMBMB)
- Tunisian Association of Biological Sciences (ATSB)
## COMPOSITION OF THE FEBS COMMITTEES AND WORKING GROUPS
### AND THE GEOGRAPHICAL DISTRIBUTION OF THE MEMBERS

**APPENDIX 3**

January 1, 2022 - December 31, 2022

* = term ends / position for (re-)election to start 1.1.2023

<table>
<thead>
<tr>
<th>EXECUTIVE COMMITTEE</th>
<th>Country</th>
<th>Elected in</th>
<th>Starting</th>
<th>Ending</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piotr Laidler</td>
<td>Poland</td>
<td>Krakow (2019)</td>
<td>01 01 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Chairperson</td>
<td></td>
<td></td>
<td>01 01 20</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Vice-Chair</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janko Kos</td>
<td>Slovenia</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Vice-Chair</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Václav Pařes,</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Secretary General</td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Secretary-General-Elect</td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 16</td>
</tr>
<tr>
<td>Frank Michelangeli</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Treasurer</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Acting Treasurer</td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Miguel A. De la Rosa</td>
<td>Spain</td>
<td>online (2021)</td>
<td>01 01 23</td>
<td>31 12 25</td>
</tr>
<tr>
<td>Secretary General</td>
<td></td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Congress Counsellor</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Beata Vertessy</td>
<td>Hungary</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Chair, Advanced Courses Committee</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Acting Chair</td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Alain Krol</td>
<td>France</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Chair, Fellowships Committee</td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Johannes Buchner</td>
<td>Germany</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Chair, Publications Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emmanouil Fragkouls</td>
<td>Greece</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Chair, Science &amp; Society Committee</td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Ferhan Sağın</td>
<td>Turkey</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Chair, Education Committee</td>
<td></td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>31 12 21</td>
</tr>
<tr>
<td>Cecilia Arsiano</td>
<td>Portugal</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Chair, Women in Science Working Group (WiSe)</td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Acting Chair</td>
<td></td>
<td>St. Petersburg (2013)</td>
<td>01 01 14</td>
<td>31 12 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seville (2012)</td>
<td>11 09 12</td>
<td>31 12 13</td>
</tr>
<tr>
<td>Jerka Dumić Chair, Working Group on Integration (WGI)</td>
<td>Croatia</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Acting Chair</td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Irene Díaz-Moreno</td>
<td>Spain</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Chair, Working Group on the Careers of Young Scientists</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Xavier Coumoul</td>
<td>France</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Chair, Network Working Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel Pecht</td>
<td>Israel</td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>-</td>
</tr>
<tr>
<td>Honorary member</td>
<td></td>
<td>Seville (2012)</td>
<td>01 01 14</td>
<td>31 12 16</td>
</tr>
<tr>
<td>(non-voting, non-Director, non-Trusted role)</td>
<td></td>
<td>Prague (2009)</td>
<td>01 01 11</td>
<td>31 12 13</td>
</tr>
<tr>
<td>Secretary General</td>
<td></td>
<td>Istanbul (2006)</td>
<td>01 01 08</td>
<td>31 12 10</td>
</tr>
<tr>
<td>ADVANCED COURSES COMMITTEE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beata Vertessy, Chair</td>
<td>Hungary</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>St Petersburg (2013)</td>
<td>08 08 13</td>
<td>31 12 14</td>
</tr>
<tr>
<td>Mutay Aslan</td>
<td>Turkey</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Antonio Díaz-Quintana</td>
<td>Spain</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>João Laranjinha</td>
<td>Portugal</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Mauro Maccarone</td>
<td>Italy</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Kristina Mäkinen</td>
<td>Finland</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Damjana Rozman</td>
<td>Slovenia</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio)</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Treasurer</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Acting Treasurer</td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio)</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Secretary General</td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATION COMMITTEE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferhan Sağın</td>
</tr>
<tr>
<td>Chair, Education Committee member</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Manuel João Costa</td>
</tr>
<tr>
<td>Erkki Raulo</td>
</tr>
<tr>
<td>Néstor Torres</td>
</tr>
<tr>
<td>Ludiane Vieira de Mello</td>
</tr>
<tr>
<td>Xavier Coumoul (Co-opted)</td>
</tr>
<tr>
<td>Wimme Eskild (Co-opted)</td>
</tr>
<tr>
<td>Nino Sinjić (Co-opted)</td>
</tr>
<tr>
<td>Angel Herrández (Co-opted, non-voting)</td>
</tr>
<tr>
<td>Keith Elliott (Co-opted, non-voting)</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio)</td>
</tr>
<tr>
<td>Treasurer</td>
</tr>
<tr>
<td>Acting Treasurer</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio)</td>
</tr>
<tr>
<td>Secretary General</td>
</tr>
<tr>
<td>Beata Vertessy Chair, Advanced Courses (Ex-officio)</td>
</tr>
<tr>
<td>Acting Chair, ACC</td>
</tr>
<tr>
<td>Jerka Đumić (Ex-officio)</td>
</tr>
<tr>
<td>Chair, Working Group on Integration</td>
</tr>
</tbody>
</table>
### FELLOWSHIPS COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
<th>Start Date 1</th>
<th>Start Date 2</th>
<th>End Date 1</th>
<th>End Date 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alain Krol, Chair</td>
<td>France</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>01 01 17</td>
<td>*31 12 22</td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tihomir Balog</td>
<td>Croatia</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 24</td>
<td></td>
</tr>
<tr>
<td>Rita Casadio</td>
<td>Italy</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td>Valeriy Filonenko</td>
<td>Ukraine</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 24</td>
<td></td>
</tr>
<tr>
<td>Marie-Theres Hauser</td>
<td>Austria</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>Jussi Hepojoki</td>
<td>Finland</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td></td>
<td>31 12 25</td>
<td></td>
</tr>
<tr>
<td>Sebastian Hiller</td>
<td>Germany</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 24</td>
<td></td>
</tr>
<tr>
<td>Jolanta Jura (Co-opted)</td>
<td>Poland</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td></td>
<td>31 12 19</td>
<td></td>
</tr>
<tr>
<td>Dimitris Kletsas</td>
<td>Greece</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td>Maciej Lalowski</td>
<td>Finland</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>Marek Mráz</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>Cedric Notredame</td>
<td>Spain</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td>Nesrin Kartal Ozer</td>
<td>Turkey</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 24</td>
<td></td>
</tr>
<tr>
<td>Vicente Rubio</td>
<td>Spain</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>Graça Soval</td>
<td>Portugal</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td>Ayfer Yalcın (Co-opted)</td>
<td>Turkey</td>
<td>Co-opted</td>
<td>01 01 22</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td></td>
<td>31 12 22</td>
<td></td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio) Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td></td>
<td>31 12 20</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td></td>
<td>31 12 17</td>
<td></td>
</tr>
<tr>
<td>Václav Paříš (Ex-Officio) Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td></td>
<td>31 12 19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td></td>
<td>31 12 16</td>
<td></td>
</tr>
</tbody>
</table>

### FINANCE COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
<th>Start Date 1</th>
<th>Start Date 2</th>
<th>End Date 1</th>
<th>End Date 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Michelangeli, Chair Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>01 01 18</td>
<td>31 12 23</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td></td>
<td></td>
<td>31 12 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesco Bonomi</td>
<td>Italy</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 24</td>
<td></td>
</tr>
<tr>
<td>Joel Sussman</td>
<td>Israel</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>Václav Paříš (Ex-Officio) Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td></td>
<td>31 12 19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td></td>
<td>31 12 16</td>
<td></td>
</tr>
<tr>
<td>Johannes Buchner (Ex-Officio) Chair, Publications Committee</td>
<td>Germany</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
<td>31 12 23</td>
<td></td>
</tr>
<tr>
<td>László Fésüs (Co-opted)</td>
<td>Hungary</td>
<td>Co-opted</td>
<td>01 01 21</td>
<td></td>
<td>*31 12 22</td>
<td></td>
</tr>
</tbody>
</table>
### PUBLICATIONS COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
<th>Elected</th>
<th>Expired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johannes Buchner, Chair</td>
<td>Germany</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Marc Baumann</td>
<td>Finland</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Consuelo Guerri</td>
<td>Spain</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Johannes Herrmann</td>
<td>Germany</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td>31 12 25</td>
</tr>
<tr>
<td>Marcin Majka</td>
<td>Poland</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td>31 12 25</td>
</tr>
<tr>
<td>George Mosialos</td>
<td>Greece</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio) Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio) Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 16</td>
</tr>
</tbody>
</table>

### SCIENCE AND SOCIETY COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
<th>Elected</th>
<th>Expired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emmanouil Fragkoulis, Chair</td>
<td>Greece</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td>Mauro Torti</td>
<td>Italy</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Melita Vidaković</td>
<td>Serbia</td>
<td>online (2021)</td>
<td>01 01 22</td>
<td>31 12 25</td>
</tr>
<tr>
<td>Enrique Viguera Minguez</td>
<td>Spain</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 24</td>
</tr>
<tr>
<td>Raffaele Porta (Co-opted)</td>
<td>Italy</td>
<td>Co-opted (2021)</td>
<td>01 01 22</td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 21</td>
</tr>
<tr>
<td>Isabel Varela-Nieto (Co-opted)</td>
<td>Spain</td>
<td>Co-opted</td>
<td>01 01 21</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio) Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td>31 12 17</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio) Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 16</td>
</tr>
<tr>
<td>Miguel A. De la Rosa Congress Counsellor (Ex-Officio)</td>
<td>Spain</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td>31 12 17</td>
</tr>
</tbody>
</table>

### WORKING GROUP ON CAREERS OF YOUNG SCIENTISTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
<th>Elected</th>
<th>Expired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irene Díaz-Moreno, Chair</td>
<td>Spain</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>31 12 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td>31 12 20</td>
</tr>
<tr>
<td>Anna Jagusiak (Co-opted)</td>
<td>Poland</td>
<td>Co-opted</td>
<td>01 06 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Vlastimil Kulda (Co-opted)</td>
<td>Czech Republic</td>
<td>Co-opted</td>
<td>01 06 21</td>
<td>*31 12 22</td>
</tr>
<tr>
<td>Jerka Dumic (Co-opted)</td>
<td>Croatia</td>
<td>Co-opted</td>
<td>01 01 22</td>
<td>31 12 23</td>
</tr>
<tr>
<td>Name</td>
<td>Office</td>
<td>Country</td>
<td>City</td>
<td>Date</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>-------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio)</td>
<td>Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio)</td>
<td>Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td></td>
</tr>
<tr>
<td>Jerka Dumić, Chair</td>
<td></td>
<td>Croatia</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 18</td>
</tr>
<tr>
<td>Aleš Berlec</td>
<td></td>
<td>Slovenia</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
</tr>
<tr>
<td>Tatiana Borisova</td>
<td></td>
<td>Ukraine</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
</tr>
<tr>
<td>Frank Michelangeli (Ex-Officio)</td>
<td>Treasurer</td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
</tr>
<tr>
<td>Václav Pařes (Ex-Officio)</td>
<td>Secretary General</td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td></td>
</tr>
<tr>
<td>Ferhan Sagin (Ex-Officio)</td>
<td>Chair, Education Committee</td>
<td>Turkey</td>
<td>online (2021)</td>
<td>01 01 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prague (2018)</td>
<td></td>
</tr>
<tr>
<td>Beata Vertesy (Ex-Officio)</td>
<td>Chair, Advanced Courses Committee</td>
<td>Hungary</td>
<td>online (2020)</td>
<td>01 01 21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>St Petersberg (2013)</td>
<td>08 08 13</td>
</tr>
<tr>
<td>Xavier Couroubleau, Chairperson</td>
<td></td>
<td>France</td>
<td>online (2021)</td>
<td>01 01 22</td>
</tr>
<tr>
<td>Andrea Bellielli</td>
<td></td>
<td>Italy</td>
<td>Prague (2018)</td>
<td>01 01 19</td>
</tr>
<tr>
<td>Ali Burak Özkan</td>
<td></td>
<td>Turkey</td>
<td>online (2021)</td>
<td>01 01 22</td>
</tr>
<tr>
<td>László Nyitrai (Delegated)</td>
<td>(ex-Fellowships Committee)</td>
<td>Hungary</td>
<td>Delegated</td>
<td>01 01 22</td>
</tr>
<tr>
<td>Enrique Viguera Minguez (Delegated)</td>
<td>(Science and Society Committee)</td>
<td>Spain</td>
<td>Delegated</td>
<td>01 01 22</td>
</tr>
<tr>
<td>Boris Turk (Delegated)</td>
<td>(ex-Publications Committee)</td>
<td>Slovenia</td>
<td>Delegated</td>
<td>01 01 18</td>
</tr>
<tr>
<td>László Fésüs (Co-opted)</td>
<td>(former Chair, FEBS Network WG)</td>
<td>Hungary</td>
<td>Co-opted</td>
<td>01 01 22</td>
</tr>
<tr>
<td>Irene Díaz-Moreno (Co-opted)</td>
<td>Chair, Working Group on the Careers of Young Scientists</td>
<td>Spain</td>
<td>online (2020)</td>
<td>01 01 21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
</tr>
<tr>
<td>Name</td>
<td>Country</td>
<td>Location</td>
<td>Date</td>
<td>Details</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td><strong>Beata Vertessy (Co-opted)</strong></td>
<td>Hungary</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td>Jerusalem (2017)</td>
</tr>
<tr>
<td>Chair, Advanced Courses Committee</td>
<td></td>
<td></td>
<td>01 01 18</td>
<td>Paris (2014)</td>
</tr>
<tr>
<td>Acting Chair, ACC</td>
<td></td>
<td></td>
<td>01 01 15</td>
<td>St Petersburg (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>08 08 13</td>
<td>01 01 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 14</td>
</tr>
<tr>
<td><strong>WORKING GROUP ON WOMEN IN SCIENCE (WISE)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cecilia Maria Arraiano, Chair</strong></td>
<td>Portugal</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
</tr>
<tr>
<td>Acting Chair</td>
<td></td>
<td>Munich (2016)</td>
<td>01 01 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>St. Petersburg (2013)</td>
<td>01 01 14</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seville (2012)</td>
<td>11 09 12</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 13</td>
</tr>
<tr>
<td><strong>Frank Michelangeli (Ex-Officio)</strong></td>
<td>United Kingdom</td>
<td>online (2020)</td>
<td>01 01 21</td>
<td></td>
</tr>
<tr>
<td>Treasurer</td>
<td></td>
<td>Jerusalem (2017)</td>
<td>01 01 18</td>
<td></td>
</tr>
<tr>
<td>Acting Treasurer</td>
<td></td>
<td>Munich (2016)</td>
<td>09 09 16</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 17</td>
</tr>
<tr>
<td><strong>Václav Pačes (Ex-Officio)</strong></td>
<td>Czech Republic</td>
<td>Krakow (2019)</td>
<td>01 01 20</td>
<td></td>
</tr>
<tr>
<td>Secretary General</td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris (2014)</td>
<td>01 01 15</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*31 12 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 12 16</td>
</tr>
</tbody>
</table>
### Appendix 4 - FEBS Fellowships 2022

#### FEBS Excellence Award

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Mobility history</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>Germany, USA</td>
</tr>
<tr>
<td>Germany</td>
<td>USA, Netherlands</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Belgium</td>
</tr>
<tr>
<td>France</td>
<td>UK</td>
</tr>
<tr>
<td>Portugal</td>
<td>USA, Netherlands</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Belgium</td>
</tr>
<tr>
<td>Austria</td>
<td>Germany</td>
</tr>
<tr>
<td>Belgium</td>
<td>Belgium &amp; Switzerland</td>
</tr>
</tbody>
</table>

#### FEBS Long Term fellows

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Czech Republic</td>
<td>Germany</td>
</tr>
<tr>
<td>2 Germany</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>3 Spain</td>
<td>Germany</td>
</tr>
<tr>
<td>4 France</td>
<td>Netherlands</td>
</tr>
<tr>
<td>5 Netherlands</td>
<td>Switzerland</td>
</tr>
</tbody>
</table>

#### FEBS Summer Short-Term fellowships

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Hungary</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>2 Spain</td>
<td>Sweden</td>
</tr>
<tr>
<td>3 Spain</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>4 Portugal</td>
<td>Israel</td>
</tr>
<tr>
<td>5 Greece</td>
<td>Germany</td>
</tr>
<tr>
<td>6 United Kingdom</td>
<td>Netherlands</td>
</tr>
<tr>
<td>7 Spain</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>8 Germany</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>9 Germany</td>
<td>Spain</td>
</tr>
<tr>
<td>10 Israel</td>
<td>France</td>
</tr>
</tbody>
</table>

#### FEBS Collaborative Developmental

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Serbia</td>
<td>Denmark</td>
</tr>
<tr>
<td>2 Armenia</td>
<td>Germany</td>
</tr>
<tr>
<td>3 Tunisia</td>
<td>Netherlands</td>
</tr>
<tr>
<td>4 Armenia</td>
<td>France</td>
</tr>
</tbody>
</table>

#### FEBS Ukrainian Short-Term Fellowship 2022

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Ukraine</td>
<td>France</td>
<td>4 months</td>
</tr>
<tr>
<td>2 Ukraine</td>
<td>Austria</td>
<td>3 months</td>
</tr>
<tr>
<td>3 Ukraine</td>
<td>Poland</td>
<td>3 months</td>
</tr>
<tr>
<td>4 Ukraine</td>
<td>Poland</td>
<td>3 months</td>
</tr>
<tr>
<td>5 Ukraine</td>
<td>United Kingdom</td>
<td>3 months</td>
</tr>
<tr>
<td>6 Ukraine</td>
<td>Poland</td>
<td>4 months</td>
</tr>
<tr>
<td>7 Ukraine</td>
<td>Germany</td>
<td>4 months</td>
</tr>
<tr>
<td>8 Ukraine</td>
<td>Belgium</td>
<td>4 months</td>
</tr>
<tr>
<td>9 Ukraine</td>
<td>Germany</td>
<td>4 months</td>
</tr>
<tr>
<td>10 Ukraine</td>
<td>Austria</td>
<td>4 months</td>
</tr>
<tr>
<td>Course Name</td>
<td>Location</td>
<td>CO Course organiser</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>The New Microbiology</td>
<td>Spetses Island, Greece</td>
<td>Pascale Cossart</td>
</tr>
<tr>
<td>Ion channels and transporters: from molecule to human - hybrid</td>
<td>Erice, Italy</td>
<td>Stephan Pless</td>
</tr>
<tr>
<td>Molecular Mechanisms of Host-pathogen Interactions and Virulence in Human Fungal Pathogens</td>
<td>La Colle sur Loup, France</td>
<td>Dr Guilhem Janbon</td>
</tr>
<tr>
<td>Ageing and Regeneration</td>
<td>Obergurgl, Austria</td>
<td>Piddler Jansen-Dürr</td>
</tr>
<tr>
<td>FEBS Advanced Lecture Course: 4th Danube Conference on Epigenetics</td>
<td>Budapest, Hungary</td>
<td>Tamás Arányi</td>
</tr>
<tr>
<td>FEBS Workshop: Proteolysis: at the interface between health and disease</td>
<td>Bled, Slovenia</td>
<td>Prof Boris Turk</td>
</tr>
<tr>
<td>Functional Imaging of cellular dynamics</td>
<td>Netherlands</td>
<td>Prof Mark Hink</td>
</tr>
<tr>
<td>Lipids, Proteins and their Interactions in Organellar Biology</td>
<td>Spetses Island</td>
<td>Prof Dr. Edjan Breukink</td>
</tr>
<tr>
<td>Molecular mechanisms of interorgan crosstalk in Health and disease * see notes</td>
<td>Spetses Island</td>
<td>Prof Dr Stefan Rose-John</td>
</tr>
<tr>
<td>Matrix Pathobiology, Signaling and Molecular Targets</td>
<td>Crete</td>
<td>Nikos Karmanos</td>
</tr>
<tr>
<td>Mitochondria in Life, Death and Disease</td>
<td>Budva, Montenegro</td>
<td>Prof Aleksandra Trifunovic</td>
</tr>
<tr>
<td>Venice Summer School 2021: The Character Concept in Metabolic, Physiological, and Developmental Evolution</td>
<td>Venice</td>
<td>Dr Berta Vard/Dr Johannes Jaeger</td>
</tr>
<tr>
<td>Molecular Mechanisms of Signal Transduction and Cancer</td>
<td>Spetses Island</td>
<td>Prof dr ir Boudewijn Burgersing</td>
</tr>
<tr>
<td>360° Lysosome; from structure to genomics, from function to disease: update</td>
<td>Kusadasi/Izmir Turkey</td>
<td>Ozmen, Eser</td>
</tr>
<tr>
<td>4th International Conference on the Long and the Short of Non-Coding RNAs</td>
<td>Rhodes</td>
<td>Thomas-Tikhonenko, Andrei</td>
</tr>
<tr>
<td>FEBS Advanced Lecture Course on Biological Surfaces and Interfaces: Forces at biological Interfaces</td>
<td>Sant Feli de Guixols, Spain</td>
<td>Gourdon, Delphine</td>
</tr>
<tr>
<td>Biomolecules in action III</td>
<td>Hamburg</td>
<td>Prof Dr Christian Betze</td>
</tr>
<tr>
<td>FEBS Practical course &quot;Microspectroscopy: Functional Imaging of Biological Systems&quot;</td>
<td>Wageningen</td>
<td>Dr Jan Willem Borst</td>
</tr>
<tr>
<td>Crosstalk between Nucleus and Mitochondria in Human Disease</td>
<td>Seville</td>
<td>Dr Irene Diaz-Moreno</td>
</tr>
<tr>
<td>FEBS Advanced Lecture Course on “Redox alterations and cellular responses: From signalling to interventions”</td>
<td>Spetses Island</td>
<td>Dr Aphrodite Vasilaki</td>
</tr>
<tr>
<td>Exploring the human proteome with antibodies, transcriptomics and mass spectrometry</td>
<td>Stockholm</td>
<td>Prof. Mathias Uhlen</td>
</tr>
<tr>
<td>Molecular targets for anti-aging interventions</td>
<td>Spetses Island</td>
<td>Dr Aleksandra Mladenovic Djordjevic</td>
</tr>
<tr>
<td>Lost in Integration - probing biomolecules with electrons, photons, neutrons and magnetic spins</td>
<td>Spetses Island</td>
<td>Prof. Poul Nissen</td>
</tr>
<tr>
<td>Total YTF</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>